Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download Lung Cancer
Document related concepts
no text concepts found
Transcript
SWOG PUBLICATIONS LIST LUNG COMMITTEE 2017 ________________________________________________________________________________________________________ PROTOCOL PROTOCOL PROTOCOL NUMBER PUBLICATIONS (TITLE & CITATION) ACTIVATED CLOSED ________________________________________________________________________________________________________ LUNG MANUSCRIPTS PUBLISHED/ACCEPTED (2017) Multiple*/Other A pooled analysis of individual patient data of concurrent chemoradiotherapy for stage 3 non-small-cell lung cancer in elderly patients compared to younger patients who participated in United States National Cancer Institute Cooperative Group studies. TE Stinchcombe, Y Zhang, EE Vokes, J Schiller, JD Bradley, Karen Kelly, W Curran, SE Schild, B Movsas, G Clamon, R Govindan, GR Blumenschein, MA Socinski, NE Ready, WL Akerley, HJ Cohen, H Pang, X Wang. Journal of Clinical Oncology, in press. [*S0023]. LUNG MANUSCRIPTS SUBMITTED (2017) S0819 A randomized, phase III study of carboplatin/paclitaxel or carboplatin/ paclitaxel/ bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer: SWOG S0819. R Herbst, M Redman, E Kim, T Semrad, L Bazhenova, G Masters, K Oettel, P Guaglianone, C Reynolds, A Karnad, S Arnold, M VarellaGarcia, J Moon, P Mack, C Blanke, F Hirsch, K Kelly, DR Gandara. Journal of Clinical Oncology, submitted 3/6/17. S0905 Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905). A Tsao, J Moon, II Wistuba, NJ Vogelzang, GP Kalemkerian, MW Redman, DR Gandara, Karen Kelly. Journal of Thoracic Oncology, submitted 3/10/17. LUNG ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2017) S0424 Steroid hormone receptor protein expression by gender 10/1/05 and smoking in non-small cell lung cancer: SWOG S0424. T-Y D Cheng, AK Darke, MW Redman, GR Zirpoli, W Davis, R Payne Ondracek, W Bshara, R Kratzke, JR Molina, JM Kolesar, Y Chen, RM MacRae, J Moon, P Mack, DR Gandara, K Kelly, RM Santella, KS Albain, CB Ambrosone. USCAP 2017 (March 4-10, 2017, San Antonio, TX), poster. 3/15/11 S1400A A phase II study of Durvalumab (MEDI4736) for previously 6/15/14 treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A. V Papadimitrakopoulou, MW Redman, H Borghaei, SN Waqar, F Robert, GJ Kiefer, S McDonough, RS Herbst, K Kelly, DR Gandara. European Lung Cancer Conference (May 5-7, 2017, Geneva, Switzerland), accepted, oral presentation. 11/18/15 LUNG ABSTRACTS SUBMITTED (2017) (under embargo pending acceptance notification) SWOG PUBLICATIONS LIST LUNG COMMITTEE 2016 ________________________________________________________________________________________________________ DATE DATE PROTOCOL PROTOCOL PROTOCOL NUMBER PUBLICATIONS (TITLE & CITATION) ACTIVATED CLOSED ________________________________________________________________________________________________________ LUNG MANUSCRIPTS PUBLISHED (2016) S0709 SWOG S0709: Randomized phase II trial of erlotinib vs. 12/1/08 erlotinib plus carboplatin/paclitaxel in patients with advanced non-small cell lung cancer and impaired performance status as selected by a serum proteomics assay. PN Lara Jr., J Moon, P Hesketh, MW Redman, SK Williamson, WL Akerley, III, FR Hirsch, PC Mack, DR Gandara. Journal of Thoracic Oncology, Mar;11(3):420-425, 2016. 2015 Dec 24 [Epub ahead of print]. PMID: 26725184; PMC4775366 http://www.ncbi.nlm.nih.gov/pubmed/26725184 9/15/14 Multiple* Disease control rate at 8 weeks predicts subsequent survival in platinum-treated extensive stage small cell lung cancer (ES-SCLC): A patient level analysis of SWOG trials. PN Lara, Jr., J Moon, MW Redman, TJ Semrad, K Kelly, JW Allen, BJ Gitlitz, PC Mack, DR Gandara. Clinical Lung Cancer, Mar;17(2):113-118, 2016. 2015 Oct 20 [Epub ahead of print]. PMID26498504; PMC4789142 *Studies: S0327, S0435, S0802 http://www.ncbi.nlm.nih.gov/pubmed/26498504 n/a n/a n/a n/a Multiple/other Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012. HH Pang, X Wang,T Stinchcombe, M Wong, P Cheng, AK Ganti, D Sargent, Y Zhang, C Hu, S Mandrekar, M Redman, J Manola, R Schilsky, H Cohen, J Bradley, A Adjei, D Gandara, S Ramalingam, E Vokes. Journal of Clinical Oncology 2016 Sep 19 [Epub ahead of print]. PMID27646951 https://www.ncbi.nlm.nih.gov/pubmed/27646951 Multiple*/Other Overview of thoracic oncology trials in cooperative groups around the globe. AA Salahudeen, MI Patel, P Baas, WJ Curran, JD Bradley, DR Gandara, GD Goss, TS Mok, SS Ramalingam, EE Vokes, SM Malik, HA Wakelee. Clinical Lung Cancer 2016 Jun 27 [Epub ahead of print]. *S1400, S1403 and “SILENT” trial (in development) PMID27473736; PMC n/a – review article http://www.ncbi.nlm.nih.gov/pubmed/27473736 LUNG ABSTRACTS PUBLISHED/PRESENTED (2016) S0124 Impact of platinum-sensitivity status on post-progression 11/1/02 3/1/07 survival (PPS) of patients with extensive stage small cell lung cancer (ES-SCLC): results from SWOG 0124, a phase III trial of irinotecan/cisplatin(IP) vs. etoposide/cisplatin(EP). PN Lara, Jr., J Miao, J Moon, MR Redman, DR Gandara, KR Kelly. World Conference on Lung Cancer (Dec 4-7, 2016, Vienna, Austria), oral presentation. http://library.iaslc.org/virtual-library-search?product_id=6&author=lara&category= S0819 Role of KRAS mutation status in NSCLC patients treated on 7/15/09 5/1/15 S0819, a phase II trial of chemotherapy with or without cetuximab. PC Mack, J Moon, RS Herbst, ES Kim, TJ Semrad, MW Redman, RA Tsai, LJ Solis, JP Gregg, SL Hatcher, M Varella-Garcia, FR Hirsch, C Blanke, K Kelly, DR Gandara. World Conference on Lung Cancer (Dec 4-7, 2016, Vienna, Austria), poster. http://library.iaslc.org/virtual-library-search?product_id=6&author=gandara&category= S0819 Outcomes for patients treated with or without bevacizumab 7/15/09 on SWOG S0819: a randomized, phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC) . TJ Semrad, MW Redman, R Herbst, ES Kim, L Bazhenova, G Masters, K Oettel, P Guaglianone, C Reynolds, A Karnad, SM Arnold, M VarellaGarcia, J Moon, P Mack, C Blanke, F Hirsch, K Kelly, D Gandara. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session. J Clin Oncol 34, 2016 (suppl; abstr 9082). http://abstract.asco.org/176/AbstView_176_164696.html 5/1/15 S0819 Biomarker-enriched efficacy of cetuximab-based therapy: 7/15/09 squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC. FR Hirsch, MW Redman, RS Herbst, ES Kim, TJ Semrad, L Bazhenova, G Masters, K Oettel, P Guaglianone, C Reynolds, A Karnad, SM Arnold, M Varella-Garcia, J Moon, PC Mack, C Blanke, K Kelly, DR Gandara. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session. J Clin Oncol 34, 2016 (suppl; abstr 9090) http://abstract.asco.org/176/AbstView_176_169187.html 5/1/15 S1206 SWOG S1206: A dose-finding study of veliparib (ABT-888) added to chemoradiotherapy (CRT) with carboplatin (C) and paclitaxel (P) for unresectable stage III non-small cell lung cancer (NSCLC). M Cristea, Ji Miao, A Argiris, AM Chen, M Daly, R Decker, L Garland, D Wang, M Koczywas, J Moon, K Kelly, D Gandara. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session. J Clin Oncol 34, 2016 (suppl; abstr 8537) http://abstract.asco.org/176/AbstView_176_167477.html n/a 10/1/12 S1400 Lung-MAP (S1400) lung master protocol: accrual and 6/15/14 n/a genomic screening updates. V Papadimitrakopoulou, M Redman, D Gandara, F Hirsch, P Mack, H Borghaei, C Langer, J Wade, M Edelman, K Albain, P Lara Jr., C Aggarwal, M Socinski, S Gettinger, L Bazhenova, S Malik V Miller, S McDonough, E. Sigal, K Kelly, R Herbst. World Conference on Lung Cancer (Dec 4-7, 2016, Vienna, Austria), oral presentation. http://library.iaslc.org/virtual-library-search?product_id=6&author=Papadimitrakopoulou&category= S1400 Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, 6/15/14 demographics, and molecular markers. V Papadimitrakopoulou, M Redman, D Gandara, F Hirsch, P Mack, H Borghaei, C Langer, JA Engelman, M Edelman, K Albain, P Lara Jr, C Aggarwal, Mark Socinski, S Gettinger, L Bazhenova, S Malik, S McDonough, EV Sigal, K Kelly, R Herbst. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session. J Clin Oncol 34, 2016 (suppl; abstr 9088) http://abstract.asco.org/176/AbstView_176_170178.html S1403 Afatinib with or without cetuximab for first-line treatment of 3/25/15 n/a advanced EGFR-mutant NSCLC: Interim Results of SWOG S1403. S Goldberg, J Moon, R Lilenbaum, K Politi, MA Melnick, T Stinchcombe, L Horn, E Chen, J Miao, M Redman, K Kelly, D Gandara. World Conference on Lung Cancer (Dec 4-7, 2016, Vienna, Austria), poster. http://library.iaslc.org/virtual-library-search?product_id=6&author=goldberg&category= E1505 E1505: Adjuvant chemotherapy +/- bevacizumab for early 7/1/07 stage NSCLC—Outcomes based on chemotherapy subsets. H Wakelee, S Dahlberg, S Keller, W Tester, D Gandara, S Graziano, A Adjei, N Leighl, C Butts, S Aisner, J Rothman, J Patel, M Sborov, R McDermott, R Perez-Soler, A Traynor, T Evans, L Horn, S Ramalingam, J Schiller. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral session. J Clin Oncol 34, 2016 (suppl; abstr 8507). http://meetinglibrary.asco.org/content/166472-176 n/a 9/20/13 SWOG PUBLICATIONS LIST LUNG COMMITTEE 2015 ________________________________________________________________________________________________________ DATE DATE PROTOCOL PROTOCOL PROTOCOL NUMBER PUBLICATIONS (TITLE & CITATION) ACTIVATED CLOSED ________________________________________________________________________________________________________ LUNG MANUSCRIPTS PUBLISHED/ACCEPTED (2015) S0533 A pilot trial of cisplatin/etoposide/radio therapy followed by consolidation docetaxel and the addition of bevacizumab (NSC-704865) in patients with inoperable locally advanced stage III non-small cell lung cancer: SWOG S0533. AJ Wozniak, J Moon, CR Thomas, Jr., K Kelly, PC Mack, LE Gaspar, D Raben, TJ Fitzgerald, KJ Pandya, DR Gandara. Clinical Lung Cancer Sep;16(5):340-347, 2015. 2015 Jan 9 [Epub ahead of print]. PMID25703100; PMC4497941 http://www.ncbi.nlm.nih.gov/pubmed/25703100 6/15/06 3/1/10 S0722 Phase II study of mTOR inhibitor everolimus (RAD0001) in advanced malignant pleural mesothelioma (MPM): SWOG S0722. S-H I Ou, J Moon, LL Garland, PC Mack, JR Testa, A Tsao, AJ Wozniak, DR Gandara. Journal of Thoracic Oncology 10(2):387-391, 2015. PMID25611229 PMC4304604 http://www.ncbi.nlm.nih.gov/pubmed/25611229 2/1/08 9/15/11 S1400 Lung Master Protocol (Lung-MAP)—biomarker-driven 6/15/14 protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. RS Herbst, DR Gandara, FR Hirsch, MW Redman, M LeBlanc, PC Mack, LH Schwartz, E Vokes, SS Ramalingam, JD Bradley, D Sparks, Y Zhou, C Miwa, VA Miller, R Yelensky, Y Li, JD Allen, EV Sigal, D Wholley, CC Sigman, G Blumenthal, S Malik, GJ Kelloff, JS Abrams, CD Blanke, VA Papadimitrakopoulou. Clinical Cancer Research, Apr 1;21(7):1514-24, 2015. PMID25680375; PMC4654466 http://www.ncbi.nlm.nih.gov/pubmed/25680375 n/a S1400 Innovative Clinical Trials: The LUNG-MAP Study. CE Steuer, V Papadimitrakopoulou, RS Herbst, M Redman, F Hirsch, PC Mack, SS Ramalingam, DR Gandara. Clinical Pharmacology and Therapeutics, May;97(5): 488-491, 2015. PMID25676724; “state of the art” article not within scope of Public Access Policy. http://www.ncbi.nlm.nih.gov/pubmed/25676724 6/15/14 n/a S1400 Lung-MAP--framework, overview, and design principles. R Ferrarotto, M Redman, D Gandara, R Herbst, V Papadimitrakopoulou. Chinese Clinical Oncology Sep;4(3):36, 2015. PMID26408303; PMCID n/a – review articles not within scope of Public Access Policy. http://www.ncbi.nlm.nih.gov/pubmed/26408303 6/15/14 n/a S1400/other The master protocol concept. MW Redman, CJ Allegra. Seminars in Oncology, in press. Seminars in Oncology 2015 Oct;42(5):724-730. PMID26433553 http://www.ncbi.nlm.nih.gov/pubmed/26433553 6/15/14 n/a S1400/other Squamous cell lung cancer: from tumor genomics to cancer therapeutics. [Focus article]. DR Gandara, PS Hammerman, ML Sos, PN Lara Jr, FR Hirsch. Clinical Cancer Research May 15; 21(10):2236-2243, 2015. PMID25979930; “focus” article not within scope of Public Access Policy. http://www.ncbi.nlm.nih.gov/pubmed/25979930 6/15/14 n/a S1400/other Lung cancer in the era of precision medicine. [Focus article]. 6/15/14 K Politi, RS Herbst. Clinical Cancer Research May 15;21(10): 2213-2220, 2015. PMID25979927; PMC4505624 http://www.ncbi.nlm.nih.gov/pubmed/25979927 n/a S1400/other EGFR tyrosine kinase inhibitors in squamous cell lung cancer. 6/15/14 [Commentary]. FR Hirsch, RS Herbst, DR Gandara. Lancet Oncology Aug;16(8):872-873, 2015. PMID26156654; PMC n/a; “commentary”article not within scope of Public Access Policy. http://www.ncbi.nlm.nih.gov/pubmed/26156654 n/a S1403/other Patient-derived xenografts for investigation of acquired resistance in oncogene-driven cancers: building a better mousetrap. [Editorial]. DR Gandara, PN Lara Jr, PC Mack. Journal of Clinical Oncology Sep 10;33(26):2839-2840,2015. Jul 27 [Epub ahead of print].PMID26215942; PMC n/a; editorial not within scope of Public Access Policy. http://www.ncbi.nlm.nih.gov/pubmed/26215942 n/a E4512 ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. R Govindan, SJ Mandrekar, DE Gerber, GR Oxnard, SE Dahlberg, J Chaft, S Malik, M Mooney, JS Abrams, PA Janne, DR Gandara, SS Ramalingam, EE Vokes. Clinical Cancer Research Dec 15;21(24):5439-44, 2015. PMID26672084; PMC4683399 http://www.ncbi.nlm.nih.gov/pubmed/?term=gandara+dr+alchemist Multiple* Relevance of platinum sensitivity status in relapsed/refractory n/a extensive stage small cell lung cancer (ES-SCLC) in the modern era: a patient level analysis of SWOG trials. PN Lara, Jr., J Moon, MW Redman, TJ Semrad, K Kelly, J Allen, BJ Gitlitz, PC Mack, DR Gandara. Journal of Thoracic Oncology Jan;10(1):110-115, 2015. PMID25490004; PMC4320001. *Pooled analysis of studies: S0327, S0435, S0802. http://www.ncbi.nlm.nih.gov/pubmed/25490004 n/a Multiple* Multitrial evaluation of progression-free survival as a surrogate n/a end point for overall survival in first-line extensive-stage smallcell lung cancer. NR Foster; LA Renfro, SE Schild, MW Redman, XF Wang, SE Dahlberg, K Ding, PA Bradbury, SS Ramalingam, DR Gandara, T Shibata, N Saijo, E Vokes, AA Adjei, SJ Mandrekar. Journal of Thoracic Oncology Jul;10(7):1099-1106, 2015. PMID26134227; PMC4493926 *Pooled analysis including data from S0124 http://www.ncbi.nlm.nih.gov/pubmed/26134227 n/ 6/15/14 Multiple Reply to "diminishing role of platinum-sensitivity status in n/a patients with small cell lung cancer". PN Lara, Jr., DR Gandara, MW Redman. Journal of Thoracic Oncology, 2015 May;10(5):e36. doi: 10.1097/JTO.0000000000000515. *Pooled analysis of studies: S0327, S0435, S0802. PMID25898968; PMCID not applicable; Letter to the Editor not within scope of Public Access Policy. http://www.ncbi.nlm.nih.gov/pubmed/?term=lara+pn+diminishing Multiple* Disease control rate at 8 weeks predicts subsequent survival in platinum-treated extensive stage small cell lung cancer (ES-SCLC): A patient level analysis of SWOG trials. PN Lara, Jr., J Moon, MW Redman, TJ Semrad, K Kelly, JW Allen, BJ Gitlitz, PC Mack, DR Gandara. Clinical Lung Cancer, 2015 Oct 20 [Epub ahead of print]. PMID26498504; In process at NIHMS; NIHMS732254 *Studies: S0327, S0435, S0802 http://www.ncbi.nlm.nih.gov/pubmed/26498504 n/a LUNG ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2015) S0709 SWOG 0709: A randomized phase II “pick-the-winner” 12/1/08 trial of erlotinib (ERL) vs. ERL plus carboplatin/paclitaxel (C/T) in patients (pts) with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS 2) as selected by serum proteomics. PN Lara Jr, J Moon, P Hesketh, MW Redman, SK Williamson, FR Hirsch, P Mack, DR Gandara. American Society of Clinical Oncology Annual Meeting (May 29June 2, 2015, Chicago, IL), poster session. J Clin Oncol 33:5s (suppl; abstr 8040), 2015. http://abstracts.asco.org/156/AbstView_156_143014.html 9/15/14 S0709 SWOG 0709: randomized phase II trial of erlotinib vs. 12/1/08 9/15/14 erlotinib plus carboplatin/paclitaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS2) as selected by a serum proteomics assay. PN Lara Jr, J Moon, P Hesketh, MW Redman, SK Williamson, FR Hirsch, P Mack, DR Gandara. World Conference on Lung Cancer (WCLC), (September 6-9, 2015, Denver, CO), oral presentation. Journal of Thoracic Oncology, 10(9): S322 (Suppl 2; abst MINI17.02, 2015. http://journals.lww.com/jto/Citation/2015/09001/16th_World_Conference_on_Lung_Cancer_.1.aspx S0819 A randomized, phase III study comparing carboplatin/ 7/15/09 5/1/15 paclitaxel or carboplatin/Paclitaxel/Bevacizumab with or without concurrent cetuximab in patients with advanced nonsmall cell lung cancer (NSCLC): SWOG S0819. RS Herbst, MW Redman, ES Kim, TJ Semrad, L Bazhenova, G Masters; K Oettel, P Guaglianone , C Reynolds, A Karnad, SM Arnold, M Varella-Garcia, J Moon, PC Mack, CD Blanke, FR Hirsch, DR Gandara. World Conference on Lung Cancer (WCLC), (September 6-9, 2015, Denver, CO), oral, plenary session, PLEN04:01. http://journals.lww.com/jto/Citation/2015/09001/16th_World_Conference_on_Lung_Cancer_.1.aspx S1400 Patients, investigators and pharmaceuticals working 6/15/14 together to accelerate research and access: the Lung Cancer Master Protocol (Lung-MAP) Clinical Trial. V Papadimitrakopoulou, DR Gandara, M Redman, FR Hirsch, PC Mack, H Borghaei, CJ Langer, JA Engelman, M Edelman, K Albain, P Lara Jr., C Aggarwal, MA Socinski, EV Sigal, Roy Herbst. Journal of Thoracic Oncology 10(9): S141 (Suppl 2, MTE 02), 2015. http://www.sciencedirect.com/science/journal/15560864/10/9/supp/S2 n/a S1400 Lung Master Protocol in Squamous Cell Lung Cancer 6/15/14 n/a (Lung-MAP, S1400). DR Gandara, M Redman, R Herbst, J Abrams, S Malik, E Sigal, FR Hirsch, PC Mack, V Papadimitrakopoulou. Journal of Thoracic Oncology 10(9):S80 (Suppl 2, abst ED07.03), 2015. http://journals.lww.com/jto/Citation/2015/09001/16th_World_Conference_on_Lung_Cancer_.1.aspx E4512 ALCHEMIST: a clinical trial platform to bring genomic pending discovery and molecularly targeted therapies to early-stage lung cancer. DE Gerber, GR Oxnard, SJ Mandrekar, SE Dahlberg, S Malik, M Mooney, JS Abrams, PA Jänne, T Li, SS Ramalingam , R Govindan, EE Vokes American Society of Clinical Oncology Annual Meeting (May 29June 2, 2015, Chicago, IL), poster session. J Clin Oncol 33:5s (suppl; abstr TPS7583), 2015. http://abstracts.asco.org/156/AbstView_156_147927.html SWOG PUBLICATIONS LIST LUNG COMMITTEE 2014 ________________________________________________________________________________________________________ DATE DATE PROTOCOL PROTOCOL PROTOCOL NUMBER PUBLICATIONS (TITLE & CITATION) ACTIVATED CLOSED ________________________________________________________________________________________________________ LUNG MANUSCRIPTS PUBLISHED/ACCEPTED (2014) S0220 Trimodality therapy for superior sulcus non-small cell 7/1/03 lung cancer: Southwest Oncology Group-Intergroup trial S0220. KH Kernstine, J Moon, MJ Kraut, KMW Pisters, JR Sonett, VW Rusch, CR Thomas, T Waddell, JR Jett, AP Lyss, SM Keller, DR Gandara. Annals of Thoracic Surgery 98(2): 402-410, 2014. PMID24980603; PMC4122593 http://www.ncbi.nlm.nih.gov/pubmed/24980603 10/1/07 S0720 A phase II, cooperative group, adjuvant trial using a biomarker-based decision algorithm in stage I non-smallcell lung cancer (SWOG-0720, NCT00792701). G Bepler, RG Zinner, J Moon, R Calhoun, K Kernstine, CC Williams, PC Mack, V Oliveira, Z Zheng, PJ Stella, MW Redman, DR Gandara. Cancer, 120(15):2343-2351, 2014. PMID24752945; PMC4140446 http://www.ncbi.nlm.nih.gov/pubmed/24752945 11/15/08 5/15/12 S0802 SWOG S0802: A randomized phase II trial of weekly topotecan with and without afibercept in patients with platinum-treated extensive state small cell lung cancer. J Allen, J Moon, S Gadgeel, K Kelly, P Mack, H Saba, M Mohamed, M Jahanzeb, D Gandara. Journal of Clinical Oncology 32(23):2463-2470, 2014. PMID25002722; PMC4121504 http://www.ncbi.nlm.nih.gov/pubmed/25002722 5/15/09 3/1/12 S9015_S9900/ other pooled meta-analysis Pre-operative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis of individual participant data. NSCLC Meta-analysis Collaborative Group [P. Bunn and K Pisters, SWOG collaborators]. Lancet 383(9928):1561-1571, 2014].*Multiple studies pooled analysis (multi-institutional): including SWOG studies S9900 and S9015. PMID24576776; PMC4022989 http://www.ncbi.nlm.nih.gov/pubmed/24576776 5/15/92 3/15/94 Multiple* The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative metaanalysis. MM Dias, J-P Pignon, CS Karapetis, V Boige, B Glimelius, DM Kweekel, PN Lara, P Laurent-Puig, E Martinez-Balibrea, D Pa´ez, CJA Punt, MW Redman, G Toffoli, M Wadelius, RA McKinnon, MJ Sorich. Pharmacogenomics Journal 14(5):424-431, 2014. *meta-analysis of various group studies including SWOG S0124. PMID:24709690 http://www.ncbi.nlm.nih.gov/pubmed/24709690 n/a n/a Multiple* Acquired resistance to targeted therapies against oncogenedriven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. DR Gandara, T Li, PN Lara, K Kelly, JW Riess, MW Redman, PC Mack. Clinical Lung Cancer 15(1):1-6, 2014. *includes SWOG S1300 and S1403. PMID24176733; (review/perspective not within scope of Public Access Policy). http://www.ncbi.nlm.nih.gov/pubmed/24176733 n/a n/a LUNG ABSTRACTS PUBLISHED/PRESENTED (2014) C30801 Phase III randomized, placebo controlled trial of COX-2 11/15/10 11/18/13 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Alliance). MJ Edelman, X Wang, L Hodgson, RT Cheney, M Baggstrom, T Sachdev, A Gajra, E Bertino, K Reckamp, J Molina, J Schiller, K Mitchell-Richards, P Friedman, J Ritter, E Vokes. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia PA): AACR; 2014. Abstract CT238 (oral presentation). http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=d80f3c68-d262-47288a30-668f6bb98fdb&cKey=5fae0be0-7fec-49d0-9ba8e0189745e2e1&mKey=%7b6FFE1446-A164-476A-92E7-C26446874D93%7d SWOG PUBLICATIONS LIST LUNG COMMITTEE 2013 ________________________________________________________________________________________________________ DATE DATE PROTOCOL PROTOCOL PROTOCOL NUMBER PUBLICATIONS (TITLE & CITATION) ACTIVATED CLOSED ________________________________________________________________________________________________________ LUNG MANUSCRIPTS PUBLISHED (2013) S0429 A pilot study (SWOG S0429) of weekly cetuximab and chest radiotherapy for poor-risk stage III non-small cell lung cancer. Y Chen, J Moon, KJ Pandya, K Kelly, LE Gaspar, DHM Lau, FR Hirsch, DR Gandara. Frontiers of Thoracic Oncology 3:219, 2013. PMID24010120; PMC3755267 http://www.ncbi.nlm.nih.gov/pubmed/?term=chen+y+S0429 4/1/06 8/15/09 S0526 SWOG phase II trial (S0526) of pemetrexed in patients with metastatic bronchioloalveolar carcinoma (BAC). DHM Lau, J Moon, AM Davies, R Sanborn, F Hirsch, W Franklin, J Ruzich, M Redman, DR Gandara. Clinical Lung Cancer 14(4):351-5.2013. PMID23415808; NIHMSID #580325 http://www.ncbi.nlm.nih.gov/pubmed/23415808 7/1/06 10/1/08 S0536 Phase II trial of combination carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and and bevacizumab in patients with advanced non-small cell lung cancer: SWOG S0536. ES Kim, J Moon, RS Herbst, M Redman, SR Dakhil, MR Velasco, FR Hirsch, PC Mack, K Kelly and DR Gandara. Journal of Thoracic Oncology, 8(12):1519-1528,2013. PMID:24189513; NIHMSID #580325 http://www.ncbi.nlm.nih.gov/pubmed/24189513 8/15/06 9/15/07 E5597 A randomized, double blind, placebo-controlled, phase III 12/1/00 chemoprevention trial of selenium supplementation in persons with resected stage I non-small cell lung cancer (ECOG 5597). DD Karp, SJ Lee, SM Keller, GS Wright, S Aisner, SA Belinsky, D Johnson, M Johnston, G Goodman, G Clamon, G Okawara, R Marks, E Frechette, W McCaskill-Stevens, SM Lippman, J Ruckdeschel, FR Khuri. Journal of Clinical Oncology 31(33):4179-4187, 2013. PMID24002495; PMC3821010 [also listed under Prevention Committee] http://www.ncbi.nlm.nih.gov/pubmed/24002495 11/5/09 NCIC/CTG BR19 Gefitinib versus placebo in completely resected non-small11/1/2002 cell lung cancer: results of the NCIC CTG BR19 study. GD Goss, C O’Callaghan, I Lorimer, MS Tsao, GA Masters, J Jett, MJ Edelman, R Lilenbaum, AH Choy, F Khuri, K Pisters, D Gandara, K Kernstine, C Butts, J Noble, TA Hensing, K Rowland, J Schiller, K Ding, FA Shepherd. Journal of Clinical Oncology 31(27):3320-3326, 2013. PMID23980091; PMC3770864 http://www.ncbi.nlm.nih.gov/pubmed/23980091 4/22/05 Multiple* Chemotherapy outcomes by histological subtypes of nonsmall cell lung cancer: analysis of the SWOG database for antimicrotubule-platinum therapy. K Kelly, K Chansky, P Mack, P Lara, FR Hirsch, WA Franklin, A Wozniak, MJ Edelman, SK Williamson, DR Gandara. Clinical Lung Cancer 14(6):627-635, 2013. PMID23910067. *studies: S0003, S9308, S9509, S9806 http://www.ncbi.nlm.nih.gov/pubmed/23910067 None Cooperative group clinical trials in general thoracic surgery: report from the 2012 Robert Ginsberg Clinical Trials Meeting of the General Thoracic Surgical Club. M Allen, D Wigle. Annals of Thoracic Surgery 95(2):750-756, 2013. PMID23336898; Reviews are not within the scope of the Public Access Policy] http://www.ncbi.nlm.nih.gov/pubmed/23336898 n/a n/a LUNG ABSTRACTS PUBLISHED/PRESENTED (2013) S0220 Induction chemoradiotherapy followed by consolidation 7/1/03 10/1/07 cytotoxic therapy for superior sulcus (Pancoast tumors) non-small cell lung cancer: a SWOFG-coordinated feasibility phase II intergroup trial (S0220). K Kernstine, J Moon, M Kraut, K Pisters, J Sonett, V Rusch, CR Thomas, T Waddell, J Jett, A Lyss, S Keller, D Gandara. Society of Thoracic Surgeons 2013 Annual Meeting , Jan 26-30, 2013, Los Angeles, CA), (“late-breaking” abstract), oral presentation; Annals of Thoracic Surgery 94(6):2172-2175, 2013. http://download.journals.elsevierhealth.com/pdfs/journals/0003-4975/PIIS0003497512023533.pdf S0905 A phase I study of cediranib (NSC #732208) in 3/15/10 combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma (SWOG S0905). A Tsao, J Moon, I Wistuba, N Vogelzang, G Kalemkerian, M Redman, D Gandara. American Society of Clinical Oncology Annual Meeting (May 31-June 4, 2013, Chicago, IL),poster discussion. n/a Journal of Clinical Oncology 31(suppl; abstr 7527), 2013. http://abstracts2.asco.org/AbstView_132_112450.html Multiple* Relevance of platinum (plat) sensitivity status in previously n/a treated extensive-stage small cell lung cancer (ES-SCLC) in the modern era: A patient level analysis of SWOG trials. PN Lara, Jr., J Moon, M Redman, K Kelly, J Allen, B Gitlitz, PC Mack, DR Gandara. American Society of Clinical Oncology Annual Meeting (May 31-June 4, 2013, Chicago, IL), poster discussion. Journal of Clinical Oncology 31(suppl; abstr 7511), 2013.*Studies S0327, S0435,S0802. http://abstracts2.asco.org/AbstView_132_112422.html Multiple* Disease control rate at 8 weeks predicts subsequent survival in platinum-treated extensive stage small cell lung cancer (ES-SCLC): a patient level analysis of SWOG trials. PN Lara, Jr., J Moon, MW Redman, K Kelly, J Allen, BJ Gitlitz, PC Mack, DR Gandara. Journal of Thoracic Oncology 8(suppl. 2): abstr. MO13.01; (15th World Conference on Lung Cancer, October 2013, Sydney, Australia), 2013. *Studies S0327, S0435,S0802. n/a Multiple* Multitrial evaluation of progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): an Alliance-led analysis. NR Foster, LA Renfro, SE Schild , MW Redman, XF Wang, SE Dahlberg, K Ding, PA Bradbury, SS Ramalingam DR Gandara, EE Vokes, AA Adjei, SJ Mandrekar . Journal of Clinical Oncology 31(suppl; abstr 7510), 2013. *NCI cancer cooperative groups pooled multiple studies data analysis http://abstracts2.asco.org/AbstView_132_112021.html SWOG PUBLICATIONS LIST LUNG COMMITTEE 2012 ________________________________________________________________________________________________________ DATE DATE PROTOCOL PROTOCOL PROTOCOL NUMBER PUBLICATIONS (TITLE & CITATION) ACTIVATED CLOSED ________________________________________________________________________________________________________ LUNG MANUSCRIPTS PUBLISHED (2012) S0819 Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. M Redman, J Crowley, R Herbst, F Hirsch, D Gandara. Clinical Cancer Research 18(15): 4004-4012, 2012. PMID22592956; PMC3409929. http://www.ncbi.nlm.nih.gov/pubmed/22592956 7/15/09 S8992 (RTOG 88-08) Higher biologically effective dose of radiotherapy is 6/15/90 associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. M Machtay, K Bae, B Movsas, R Paulus, E Gore, R Komaki, K Albain, W Sause, WJ Curran. Int J Radiation Oncology Biol Phys. 82(1):425-34, 2012. PMID20980108; NIHMSID250178 http://www.ncbi.nlm.nih.gov/pubmed/20980108 2/1/92 NCCTG/ SWOG Multiple Impact of disease progression date determination on progression free survival estimates in advanced lung cancer. Y Qi, A Ziegler, S Hillman, M Redman, S Schild, D Gandara, A Adjei, S Mandrekar. Cancer ,118(21):53585365, 2012 PMID22434489; PMC3481159 [studies: SWOG studies S0027, S0119, S0327, S0339, S0341, S0342, S0435] http://www.ncbi.nlm.nih.gov/pubmed/22434489 n/a Multiple* Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the “common arm” approach. PC Mack, DR Gandara, PN Lara, Jr. Expert Reviews of Anticancer Therapy 12(12):1591-1596, 2012. [Review] *Studies: S0003, S0124. PMID:23253224 ; [Reviews not within scope of Public Access Policy]. http://www.ncbi.nlm.nih.gov/pubmed/23253224 Multiple* Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. DR Gandara, T Li, PN Lara, Jr., PC Mack, K Kelly, S Miyamoto, N Goodwin, L Beckett, MW Redman. Clinical Lung Cancer 13(5):321-325, 2012. *Study: S0819/other. PMID:22677432; [Reviews not within scope of Public Access Policy]. http://www.ncbi.nlm.nih.gov/pubmed/22677432 None Cooperative group clinical trials in general thoracic surgery: n/a report from the 2012 Robert Ginsberg Clinical Trials Meeting of the General Thoracic Surgical Club. MS Allen, DA Wigle on behalf of the General Thoracic Surgery Club’s Robert Ginsberg Clinical Trials Meeting [Stephen Swisher, attendee]. Annals of Thoracic Surgery 95(2):750-756, 2013. [Review/special report] PMID:23336898; [Reviews anot within scope of Public Access Policy). http://www.ncbi.nlm.nih.gov/pubmed/23336898 n/a 7/15/09 n/a n/a n/a S0533 SWOG S0533: A pilot trial of cisplatin (C)/etoposide (E)/ 6/15/06 radiotherapy (RT) followed by consolidation docetaxel (LD) and bevacizumab (B) (NSC-704865) in three cohorts of patients (pts) with inoperable locally advanced stage III non-small cell lung cancer (NSCLC). A Wozniak, J Moon, CL Thomas, K Kelly, PC Mack, LE Gaspar, D Raben, KJ Pandya, DR Gandara. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion; J Clin Oncol 30, 2012 (suppl; abstr 7018). http://abstract.asco.org/AbstView_114_92505.html S0533 Initial cooperative group experience of bevacizumab (BEV) 6/15/06 3/1/10 plus concomitant chemoradiotherapy (CRT) in patients with inoperable locally advanced stage III non-small cell lung cancer (LA-NSCLC): preliminary results of S0533. CR Thomas, J Moon, L Gaspar, D Raben, TJ Fitzgerald, A Wozniak, K Kelly, P Mack, KJ Pandya, DR Gandara. 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology (September 6-8, 2012, Chicago, IL), oral presentation. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=af961e0d-edd2-4b48a08a-86579c4faf1a&cKey=ed6da053-e083-4df9-ab0c51cd3210ea4f&mKey=%7bE968B2E9-DA03-409D-9B81-7EFE158EB9C1%7d S0533 Initial cooperative group experience of bevacizumab (BEV) 6/15/06 plus concomitant chemoradiotherapy (CRT) in patients with inoperable locally advanced stage III non-small cell lung cancer (LA-NSCLC): preliminary results of S0533. CR Thomas, J Moon, L Gaspar, D Raben, TJ Fitzgerald, A Wozniak, K Kelly, P Mack, KJ Pandya, DR Gandara. ASTRO 2012 Annual Meeting (October 28-31, 2012, Boston, MA), oral presentation. International Journal of Radiation Oncology, Biology & Physics Vol. 84, Issue 3, Supplement, page S156, 2012. http://download.journals.elsevierhealth.com/pdfs/journals/03603016/PIIS0360301612013466.pdf S0635/0636 SWOG S0635 and S0636: Phase II trials of erlotinib 7/15/07 OSI-774)(E) and bevacizumab (B) in advanced (Adv) 7/15/07 bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), or in never-smokers with primary adv NSCLC adenocarcinoma (adenoCa). H West, J Moon, F Hirsch, PC Mack, A Wozniak, D Lau, L Fehrenbacher, M Bury, M Redman, D Gandara. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion; J Clin Oncol 30, 2012 (suppl; abstr 7517). http://abstract.asco.org/AbstView_114_97070.html S0636 Molecular marker analysis of SWOG S0636, a phase II trial 7/15/07 of erlotinib and bevacizumab in never-smokers with advanced NSCLC. PC Mack, J Moon, H West, W Franklin, M VarellaGarcia, M Wynes, A Wozniak, M Redman, F Hirsch, D Gandara. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster presentation; J Clin Oncol 30, 2012 (suppl; abstr 7552). http://chicago2012.asco.org/MeetingProgram.aspx 9/1/10 S0722 SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM). L Garland, S-H Ou, J Moon, PC Mack, J Testa, A Tsao, A Wozniak, D Gandara. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster presentation; J Clin Oncol 30, 2012 (suppl; abstr 7083). http://abstract.asco.org/AbstView_114_98343.html 9/15/11 12/1/08 3/1/10 3/1/10 8/15/11 9/1/10 S0802 SWOG 0802: A randomized phase II trial of weekly topotecan with and without AVE0005 (Aflibercept) in patients with platinum-treated extensive stage small cell lung cancer (E-SCLC). J Allen, J Moon, S Gadgeel, K Kelly, PC Mack, H Saba, MK Mohamed, D Gandara. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation; J Clin Oncol 30, 2012 (suppl; abstr 7005). http://abstract.asco.org/AbstView_114_96718.html 5/15/09 Multiple* Enrollment of older patients into therapeutic SWOG lung n/a cancer trials: comparative analysis from 1993-2008. PJ Hesketh, MW Redman, JM Unger, J Moon, DR Gandara. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster presentation; J Clin Oncol 30, 2012 (suppl; abstr 7570). http://abstract.asco.org/AbstView_114_98771.html [*Studies: S0003, S0004, S0022, S0023, S0027, S0119, S0122,S0124 S0126, S0220, S0222, S0310, S0327, S0339, S0341, S0342, S0429, S0436, S0526, S0533, S0536, S0635, S0636, S9015, S9019, S9058, S9138, S9158, S9207, S9213, S9216, S9221, S9229, S9242, S9252,S9307, S9308, S9336, S9416, C9732, JBR10, N0426, R0212] n/a n/a LUNG ABSTRACTS SUBMITTED (2012) S0220 Induction chemoradiotherapy followed by consolidation cytotoxic therapy for superior sulcus (Pancoast tumors) non-small cell lung cancer: a SWOFG-coordinated feasibility phase II intergroup trial (S0220). K Kernstine, J Moon, M Kraut, K Pisters, J Sonett, V Rusch, CR Thomas, T Waddell, J Jett, A Lyss, S Keller, D Gandara. Society of Thoracic Surgeons 2013 Annual Meeting (“late-breaking” abstract), accepted, oral presentation. 7/1/03 10/1/07 SWOG PUBLICATIONS LIST LUNG COMMITTEE 2011 ___________________________________________ _ DATE DATE PROTOCOL PROTOCOL PROTOCOL CLOSED TO NUMBER PUBLICATIONS (TITLE & CITATION) ACTIVATED PATIENT ENTRY ____________________________________________________________________________________________ LUNG MANUSCRIPTS PUBLISHED/PRESENTED (2011) S0509 Phase II study of AZD2171 in patients with malignant pleural mesothelioma: SWOG S0509. LL Garland, K Chansky, A Wozniak, A Tsao, SM Gadgeel, C Verschraegen, M DaSilva, M Redman, DR Gandara. Journal of Thoracic Oncology, 6(11):1938-1945, 2011. PMID21964533; PMC3477852 http://www.ncbi.nlm.nih.gov/pubmed/21964533 11/1/05 4/1/08 S9308/S9509 Comparison of platinum based chemotherapy in patients older and younger than 70 years of age: an analysis of Southwest Oncology Group Trials 9308 and 9509. EM Blanchard, J Moon, PJ Hesketh, K Kelly, AJ Wozniak, J Crowley, D Gandara. Journal of Thoracic Oncology, 6(1):115-120, 2011. PMID21107287; PMC3075557 (also listed under Cancer Survivorship Committee) http://www.ncbi.nlm.nih.gov/pubmed/21107287 10/15/93 3/1/96 6/1/95 4/7/99 R0214 Phase III comparison of prophylactic cranial irradiation 11/102 versus observation in patients with locally advanced nonsmall-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. EM Gore, K Bae, S Wong, A Sun, J Bonner, SE Schild, LE Gaspar, JA Bogart, M Werner-Wasik, H Choy. Journal of Clinical Oncology 29(3):272-278, 2011. PMID21135270; PMC3056462 http://www.ncbi.nlm.nih.gov/pubmed/21135270 R0214 Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced nonsmall-cell lung cancer: neurocognitive and quality-of- life analysis. A Sun, K Bae, E Gord, B Movsas, S Wong, CA Meyers, J Bonner, S Schild, L Gaspar, J Bogart, M WernerWasik, H Choy. Journal of Clinical Oncology 29:279 -286, 2011. PMID21135267; PMC3056463 http://www.ncbi.nlm.nih.gov/pubmed/21135267 None A practical guide to of the Southwest Oncology Group to n/a measure malignant pleural mesothelioma (MPM) tumors by RECIST and modified RECIST criteria. A Tsao, L Garland, M Redman, K Kernstine, D Gandara, E Marom. Journal of Thoracic Oncology, 6(3)598-601, 2011. PMID21270668; PMC3643692 http://www.ncbi.nlm.nih.gov/pubmed?term=tsao%20a%20practical%20guide 8/30/07 11/1/02 8/30/07 n/a ______________________________________________________________________________ DATE DATE PROTOCOL PROTOCOL PROTOCOL CLOSED TO NUMBER PUBLICATIONS (TITLE & CITATION) ACTIVATED PATIENT ENTRY _____________________________________________________________________________________________ LUNG ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2011) S0429 Pilot study (SWOG S0429) of weekly cetuximab 4/1/06 8/15/09 and chest radiotherapy (RT) for poor-risk stage III non-small cell lung cancer (NSCLC). Y. Chen, J. Moon, K.J. Pandya, K. Kelly, L.E. Gaspar, D.H.M. Lau, F.R. Hirsch, D.R. Gandara. ASCO 2011 annual meeting (June 4-8, 2011, Chicago, IL), poster presentation; Journal of Clinical Oncology 29: 2011 (suppl; abstr 7040). http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID= 83663 S0636 The combination of erlotinib/bevacizumab in never7/15/07 smokers with advanced lung adenocarcinoma: Southwest Oncology Group (SWOG) trial 0636. H West, J Moon, FR Hirsch, P Mack, A Wozniak, MW Redman, DR Gandara. International Association for the Study of Lung Cancer 14th World Conference on Lung Cancer (July 3-7, 2011, Amsterdam, The Netherlands), oral presentation. Journal of Thoracic Oncology, 6(6):Supplement 2, abstract MO09.03, p. S552, 2011. http://journals.lww.com/jto/Citation/2011/06001/Abstracts.1.aspx 9/1/10 *E1505 Interim report of on-study demographics and toxicity from Eastern Cooperative Oncology Group (ECOG) E1505, a phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for completely resected early stage non-small cell lung cancer (NSCLC). HA Wakelee, SE Dahlberg, SM Keller, DR Gandara, S Graziano, NB Leigh, A Adjei, J Schiller. International Association for the Study of Lung Cancer 14th World Conference on Lung Cancer (July 3-7, 2011, Amsterdam, The Netherlands), oral presentation; J Thorac Oncol. 2011; 6(6)(suppl 2): S464. ABSTRACT 042.03 9/20/13 7/1/07 http://abstracts.webges.com/myitinerary/author-87.html E1505 Interim report of on-study demographics and 7/1/07 9/20/13 toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early stage non-small cell lung cancer (NSCLC). HA Wakelee, SE Dahlberg, SM Keller, DR Gandara, SL Graziano, AA Adjei, JH Schiller. ASCO 2011 annual meeting (June 4-8, 2011, Chicago, IL), poster discussion; Journal of Clinical Oncology 29:(suppl; abstr 7013), 2011. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID= 81235 *NCCTG/ SWOG Multiple Systemic evaluation of the impact of disease n/a progression (DP) date determination on progressionfree survival (PFS) in advanced lung cancer: A joint North Central Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation. SJ Mandrekar, Y Qi, K Allen-Ziegler, n/a ______________________________________________________________________________ DATE DATE PROTOCOL PROTOCOL PROTOCOL CLOSED TO NUMBER PUBLICATIONS (TITLE & CITATION) ACTIVATED PATIENT ENTRY _____________________________________________________________________________________________ SL Hillman, MW Redman, SE Schild, DR Gandara, AA Adjei. ASCO 2011 annual meeting (June 3-7, 2011, Chicago, IL), oral presentation; Journal of Clinical Oncology 29:(suppl; abstr 7005), 2011. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID= 81867 *None Comments on PFS as a primary endpoint in cancer clinical trials. J Crowley. International Association for the Study of Lung Cancer 14th World Conference on Lung Cancer (July 3-7, 2011, Amsterdam, The Netherlands), invited oral Presentation (no abstract available). n/a n/a *None Phase II into III. MW Redman, B Goldman, M LeBlanc. n/a International Association for the Study of Lung Cancer 14th World Conference on Lung Cancer (July 3-7, 2011, Amsterdam, The Netherlands), oral presentation. Journal of Thoracic Oncology, 6(6):Supplement 2, abstract M11.4, p. S92, 2011. http://journals.lww.com/jto/Citation/2011/06001/Abstracts.1.aspx n/a *Presented SWOG PUBLICATIONS LIST LUNG COMMITTEE 2010 ________________________________________________________________________________________________________ DATE DATE PROTOCOL PROTOCOL PROTOCOL NUMBER PUBLICATIONS (TITLE & CITATION) ACTIVATED CLOSED ________________________________________________________________________________________________________ LUNG MANUSCRIPTS PUBLISHED/PRESENTED (2010) S0124 Common arm comparative outcomes analysis of Phase 3 11/1/02 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer. PN Lara, K Chansky, T Shibata, H Fukuda, T Tamura, J Crowley, MW Redman, R Natale, N Saijo, and DR Gandara. Cancer, 116(24):5710-5715, 2010. PMID20737417; PMC2994945 http://www.ncbi.nlm.nih.gov/pubmed/20737417 3/1/07 S0342 Southwest Oncology Group study S0342: phase II 7/01/04 selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced stage non-small cell lung cancer. RS Herbst, K Kelly , K Chansky, PC Mack, WA Franklin, FR Hirsch, JN Atkins, SR Dakhil, KS Albain , ES Kim, M Redman, JJCrowley, DR Gandara. Journal of Clinical Oncology, 28(31):4747-4754, 2010. PMID: 20921467; PMC3020704 http://www.ncbi.nlm.nih.gov/pubmed?term=herbst%20r%20S0342 8/01/05 S0435 Sorafenib in patients with platinum treated extensive stage 7/1/05 small cell lung cancer (SCLC): A Southwest Oncology Group (SWOG 0435) phase II trial. BJ Gitlitz, J Moon, BS Glisson, HJ Reimers, MJ Bury, JD Floyd, TK Schulz, PK Sundaram, C Ho, DR Gandara. Journal of Thoracic Oncology, 5(11): 1835-1840, 2010. PMID20881645; NIHMSID241991 http://www.ncbi.nlm.nih.gov/pubmed?term=gitlitz%20bj%20sorafenib 2/15/07 S9900 Surgery with and without induction paclitaxel and 10/15/99 carboplatin chemotherapy in early stage non-small cell lung cancer: Southwest Oncology Group trial S9900, an intergroup, randomized, phase III trial. KMW Pisters, E Vallieres, J Crowley, W Franklin, PA Bunn, RJ Ginsberg, JB Putnam, K Chansky, D Gandara. Journal of Clinical Oncology, 28(11): 1843-1849, 2010. PMC2860367; PMID20231678 http://www.ncbi.nlm.nih.gov/pubmed?term=pisters%20k%20S9900 7/15/04 JBR-10 (NCIC) Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. CA Butts, K Ding, L Seymour, P Twumasi-Ankrah, B Graham, D Gandara, DH Johnson, KA Kesler, M Green, M Vincent, Y Cormier, G Goss, B Findlay, M Johnston, MS Tsao, FA Shepherd. Journal of Clinical Oncology 289(1):29-34, 2010. PMID19922915; PMC2799232 http://www.ncbi.nlm.nih.gov/pubmed/19933915 12/1/96 4/30/01 N0426 A phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced nonsmall cell lung cancer (NSCLC): an NCCTG and SWOG Study, N0426. AA Adjei, SJ Mandrekar, GK Dy, JR Molina, A Adjei, GR Gandara, KL Ziegler, PJ Stella, KM Rowland, SE Schild, RG Sinner. Journal of Clinical Oncology 28(4):614-619, 2010. PMC2815996; PMID19841321 http://www.ncbi.nlm.nih.gov/pubmed/19841321 7/1/06 2/23/07 LUNG ABSTRACTS PUBLISHED/PRESENTED (2010) S0342/S0536 Patient selection for cetuximab in NSCLC: A 7/01/04 8/01/05 systematic review of candidate predictive biomarkers. 8/15/06 9/15/07 C Harbison, D Horak, S Maier, TJ Lynch, DR Gandara, KJ O’Byrne, R Pirker, M Weber, S Khambata-Ford. Poster presentation, American Society for Clinical Oncology, 2010 Annual Meeting; Journal of Clinical Oncology 28:15s (suppl; abstr 7548), 2010. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=5379 3 S0424 KRAS and EGFR mutations in the molecular epidemiology 10/1/05 n/a of NSCLC: Interim analysis of S0424. PC Mack, MW Redman, K Chansky, S Matsumoto, WS Holland, P Lara CB Ambrosone, D R Gandara. Journal of Clinical Oncology 28:15s, 2010 (suppl; abstr 7013). http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=4839 1 NCIC/CTG/ BR.19 A phase III randomized, double-blind, placebo-controlled trial 11/102 4/2205 of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. GD Goss, I Lorimer, MS Tsao, C J O'Callaghan, K Ding, GA Masters, DR Gandara, J R Jett, M J Edelman, F A Shepherd. Journal of Clinical Oncology, 28:18s, 2010 (suppl; abstr LBA7005). http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=48314 * Presented SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST LUNG COMMITTEE 2009 ________________________________________________________________________________________________________ DATE DATE PROTOCOL PROTOCOL PROTOCOL NUMBER PUBLICATIONS (TITLE & CITATION) ACTIVATED CLOSED ________________________________________________________________________________________________________ LUNG MANUSCRIPTS PUBLISHED/PRESENTED (2009) S0003 Japan-USA common arm analysis of paclitaxel-carboplatin 11/15/00 in advanced non-small cell lung cancer: a model for assessing population-related pharmacogenomics. D Gandara, T Kawaguchi, J Crowley, J Moon, K Furuse, M Kawahara, S Teramukai, Y Ohe, K Hubota, SK Williamson, O Gautschi, HJ Lenz, HL McLeod, P Lara, CA Coltman, M Fukuoka, N Saijo, M Fukushima, PC Mack. Journal of Clinical Oncology, 27(21):3540-3546, 2009. PMC2717760; PMID:19470925 S0124 Irinotecan/cisplatin compared with etoposide/cisplatin in extensive small-cell lung cancer: SWOG study 0124. PN Lara, R Natale, J Crowley, HJ Lenz, MW Redman, JE Carleton, J Jett, JP Kuebler, SR Dakhil, K Chansky, DR Gandara. Journal of Clinical Oncology 27(15): 2530-2535, 2009. PMC2684855; PMID:19349543 S0222 SWOG 0222: A phase II study of tirapazamine/ cisplatin/etoposide and concurrent thoracic radiotherapy for limited stage small cell lung cancer. QT Le, J Moon, M Redman, SK Williamson, PN Lara, Z Goldberg, LE Gaspar, JJ Crowley, DF Moore, Jr, DR Gandara. Journal of Clinical Oncology 27(18):3014-3019, 2009. PMCID: PMC2702233; PMID:19364954 S0339 11/1/02 11/15/02 3/1/07 9/1/03 7/24/06 Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group study (S0339). AM Davies, K Chansky, PN Lara, PH Gumerlock, JJ Crowley, KS Albain, SJ Vogel, DR Gandara. Journal of Thoracic Oncology, 4(1):87-92, 2009. PMID:19096312 1/15/04 10/1/04 S9336 Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small cell lung cancer: a phase III randomized controlled trial. KS Albain, RS Swann, VW Rusch, AT Turrisi, FA Shepherd, C Smith, Y Chen, RB Livingston, RH Feins, DR Gandara, WA Fry, G Darling, DH Johnson, MR Green, RC Miller, J Ley, WT Sause, JC Cox. Lancet 374:379-386, 2009. PMID: 19632716 5/15/94 11/30/01 Multiple Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. H Wakelee, BW Loo, KH Kernstine, JB Putnam, MJ Edelman, EE Vokes, JH Schiller, P Baas, N Saijo, A Adjei, G Goss, H Choy, DR Gandara. Clinical Lung Cancer 10(6):395-404, 2009. PMID: 19900856 n/a n/a LUNG ABSTRACTS PUBLISHED/PRESENTED (2009) *S0003 S9806 S9808 Chemotherapy outcomes by histologic subtype of non-small cell lung cancer (NSCLC): analysis of the SWOG database for antimicrotubule-platinum therapy. K Chansky, PC Mack J Crowley, PN Lara, FR Hirsch, WA Franklin, DR Gandara. Oral presentation, IASLC 13th World Conference on Lung Cancer (July 31-August 4, 2009); Journal of Thoracic Oncology 4(9): suppl 1, abst. #B2.7, S326, 2009. 11/15/00 11/1/98 6/15/98 11/15/02 11/15/99 n/a *S9900 S9900 trial update, mature analysis. KM Pisters E Vallieres, P Bunn, J Crowley, K Chansky, D Gandara. Journal of Thoracic Oncology, 4(9): Suppl 1, abst. #E9.3, S 201, 2009. Lung 10/15/99 S0124/ JCOG 9511 Cisplatin (Cis) + irinotecan (CPT11) vs. Cis + etoposide (VP16) in extensive stage small cell lung cancer (E-SCLC): final comparative outcomes analysis of JCOG 9511 and SWOG 0124. P Lara, K Chansky, T Shibata, H Fukuda, T Tamura, N Saijo, H Lenz, R Natale, J Crowley, D. Gandara. Journal of Clinical Oncology 27:15s, abst. #8027, 2009. 11/01/02 3/1/07 *S0124/ JCOG 9511 Final pooled comparative outcomes analysis of JCOG 9511 and SWOG 0124, phase III trials of cisplatin + irinotecan vs. cisplatin + etoposide in extensive stage small cell lung cancer. PN Lara, K Chansky, T Shibata, H Fukuda, T Tamura, J Saijo, HJ Lenz, R Natale, J Crowley, M Redman, DR Gandara. Journal of Thoracic Oncology 4(9):suppl 1, abst. #D5.7, S396, 2009. 11/01/02 3/1/07 S0220 Docetaxel is not feasible as consolidation therapy after cisplatin/etoposide/concurrent radiotherapy followed by surgical resection for pancoast tumors: preliminary results of SWOG 0220. MJ Kraut, J Moon, CR Thomas, J Sonett, J Jett, V Rusch, AP Lyss, H Gillenwater, S Laurie, D Gandara. Poster presentation, IASLC, 13th World Conference of Lung Cancer, Journal of Thoracic Oncology 4(9):suppl 1, abst. #PD8.2.6, S522, 2009. 7/1/03 10/1/07 S0342/0536 Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC). WA Franklin, DR Gandara, ES Kim, RS Herbst, J Moon, MW Redman, C Olsen, FR Hirsch, P Mack, K Kelly. Journal of Clinical Oncology 27:15s, abst. #11076, 2009 7/1/04 8/15/06 8/1/05 9/15/07 S0342/0536 KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. PC Mack, WS Holland, M Redman, PN Lara, LJ Snyder, FR Hirsch, WA Franklin, ES Kim, RS Herbst, DR Gandara. Journal of Clinical Oncology, abst. #8022, 2009. 7/1/04 8/15/06 8/1/05 9/15/07 7/15/04 *S0424 Biomarkers of polycyclic aromatic hydrocarbonDNA damage and cigarette smoke exposure. RM Santella, Y-J Zhang, Q Wang, M Redman, K Chansky, M Reid, W Davis, D Gandara, CA Powell, K Albain, C Ambrosone. Journal of Thoracic Oncology 4(9):suppl 1, abst. # M39.2, S164, 2009. 10/1/05 n/a *S0424 Molecular epidemiology of lung cancer. CB Ambrosone. Journal of Thoracic Oncology 4(9):suppl 1, abst. M38.5, S163, 2009. 10/1/05 n/a *S0424 Role of EGFR pathway activation in never smoking patients with lung cancer. PC Mack. Journal of Thoracic Oncology 4(9):suppl 1, Abst. M39.3, S164, 2009. 10/1/05 n/a S0509 SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. LL Garland, M Redman, A Wozniak, A Tsao, S Gadgeel, C Vershraegen, M DaSilva, K Chansky, D Gandara. Journal of Clinical Oncology 27:15s, abst. # 7511 2009 11/1/05 4/1/08 S0528 Phase I evaluation of lapatinib and everolimus in patients (pts) with advanced malignancies: Southwest Oncology Group trial S0528. CJ Hoban, A Hoering, TW Synold, V Chung, DR Gandara, AF Schott, L Kingsbury, D Lew, P LoRusso, SM Gadgeel. Journal of Clinical Oncology 27:15s, abst. #3553, 2009. 9/1/06 open S0536 Carboplatin, paclitaxel, cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC), a SWOG phase II study. D Gandara, ES Kim, RS Herbst, J Moon, MW Redman, SR Dakhil, F Hirsch, PC Mack, W Franklin, K Kelly. Journal of Clinical Oncology 27:15s, abst. #8015, 2009. 8/15/06 9/15/07 *S0536 S0536:Carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC), a SWOG phase II study. GP Kim, HC Pitot, KM Rowland, DJ Sargent, MR Mahoney, PA Philip, E Mitchell, GS Sore, TR Fitch, RM Goldberg, SR Alberts. Oral presentation, IASLC, 13th World Conference on Lung Cancer (July 31August 4, 2009); Journal of Thoracic Oncology 4(9): Suppl 1, abst. #PD3.5.5, S455, 2009. 8/15/06 9/15/07 * Presented SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 2007 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 9416 (2333) Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). VW Rusch, DJ Giroux, MJ Kraut, J Crowley, M Hazuka, T Winton, D Johnson, L Shulman, F Shepherd, C Deschamps, RB Livingston, D Gandara. Journal of Clinical Oncology 25(3):313-318, 2007. Lung 4/15/95 8/1/99 S9504 LE Gaspar. Patient demographics in HOG LUN 01-24 versus SWOG 9504: apples versus oranges. Clinical Lung Cancer 8(8):478-482, 2007. PMID: 17922970 Lung 10/15/96 12/1/98 S9718 (2338) Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group study 9718. PJ Hesketh, K Chansky, V Israel, RT Grapski, TM Mekhail, CH Spiridonidis, GM Mills, K Kelly, JJ Crowley, DR Gandara. Journal of Thoracic Oncology 2(5):440-444, 2007. Lung 7/1/98 6/15/99 S0027 (2358) Chemotherapy in patients ≥80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6. PJ Hesketh, RC Lilenbaum, K Chansky, A Dowlati, P Graham, RA Chapman, JJ Crowley, DR Gandara. Journal of Thoracic Oncology 2(6):494-498, 2007. Lung 9/01/01 7/01/03 S0119 (2361) Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. W Akerley, J McCoy, PJ Hesketh, JW Goodwin, JD Bearden, JN Atkins, K Chansky, JJ Crowley, DR Gandara. Journal of Thoracic Oncology 2(6):526-530, 2007. Lung 1/1/02 2/15/03 Multiple Studies Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. DR Gandara, AM Davies, O Gautschi, PC Mack, DH Lau, PN Lara, FR Hirsch. Clinical Lung Cancer 8 Suppl 2:S61-67, 2007 Lung n/a n/a ABSTRACTS PUBLISHED/PRESENTED S9900 (2400) S9900: surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): follow-up on a phase III trial. K Pisters, E Vallieres, PA Bunn, J Crowley, K Chansky, R Ginsberg, DR Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7520, 2007. Lung 10/15/99 7/15/04 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ S0003 (2377) Pharmacogenomic (PG) analysis of Japan-SWOG Lung common arm study in advanced stage non-small cell lung cancer (NSCLC): a model for testing populationrelated pharmacogenomics. DR Gandara, T Kawaguchi, J Crowley, J Moon, M Kawahara, S Teramukai, S Williamson, K Furuse, HL McLeod, PC Mack. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7500, 2007. 11/15/00 11/15/02 S0023 (2342) Updated analysis of SWOG 0023: a randomized phase III Lung trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. K Kelly, K Chansky, LE Gaspar, JR Jett, Y Ung , KS Albain, JJ Crowley, DR Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7513, 2007. 6/15/01 4/15/05 S0124 (2343) Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan Lung (CPT11) in extensive-stage small cell lung cancer (E-SCLC): pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124. P Lara, M Redman, H Lenz, M Gordon, T Shibata, H Fukuda, T Tamura, N Saijo, R Natale, D Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7524, 2007. 11/01/02 3/1/07 S0341 (2349) Erlotinib as initial therapy in patients with advanced nonsmall cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341). PJ Hesketh, K Chansky, AJ Wozniak, P Mack, PN Lara, WA Franklin, FR Hirsch, J Crowley, DR Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7536, 2007. Lung 9/15/04 10/01/05 S0342 (2350) A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. RS Herbst, K Chansky, K Kelly, JN Atkins, AM Davies, SR Dakhil, KS Albain, ES Kim, JJ Crowley, DR Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7545, 2007. Lung 7/01/04 8/01/05 Multiple Studies (2381) Toxicity and survival by sex in patients with advanced non small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials. KS Albain, J Unger, CC Gotay, AM Davies, M Edelman, RS Herbst, K Kelly, S Williamson, AJ Wozniak, DR Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7549, 2007. Lung *Presented SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 2006 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED S9504 (2372) Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-smallcell lung cancer: a phase II Southwest Oncology Group study (S9504). DR Gandara, K Chansky, KS Albain, LE Gaspar, PN Lara, Jr, K Kelly, J Crowley, R Livingston. Clinical Lung Cancer 8(2):116-121, 2006. S9712 (2299) Lung 10/15/96 12/1/98 Phase II study of consolidation paclitaxel after concurrent Lung chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. AM Davies, K Chansky, DHM Lau, BR Leigh, LE Gaspar, GR Weiss, AJ Wozniak, JJ Crowley, DR Gandara. Journal of Clinical Oncology 24(33):5242-5246, 2006. 2/15/98 6/1/00 S9914 (2274) Phase II trial of paclitaxel, carboplatin and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. PJ Hesketh, J McCoy, FR Dunphy II, JD Bearden III, GR Weiss, JK Giguere, JN Atkins, SR Dakhil, K Kelly, JJ Crowley, DR Gandara. Journal of Thoracic Oncology 1(9):991-995, 2006. Lung 10/15/99 6/15/01 S0027 (2203) Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). PJ Hesketh, K Chansky, DH Lau, JH Doroshow, C Moinpour, RA Chapman, JW Goodwin, HM Gross, J Crowley, DR Gandara. Journal of Thoracic Oncology 1(6):537544, 2006. Lung 9/1/01 7/1/03 S0126 (2220) Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group study S0126. HL West, WA Franklin, J McCoy, P Gumerlock, R Vance, DHM Lau, K Chansky, JJ Crowley, DR Gandara. Journal of Clinical Oncology 24(12):1807-1813, 2006. Lung 12/01/01 7/01/03 S0327 (2271) Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). PN Lara Jr, K Chansky, AM Davies, WA Franklin, PH Gumerlock, PP Guaglianone, JN Atkins, N Farneth, PC Mack, JJ Crowley, DR Gandara. Journal of Thoracic Oncology 1(9):996-1001, 2006. Lung 9/1/03 9/15/04 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ ABSTRACTS PUBLISHED/PRESENTED S0003 (2294) Elevated osteopontin (OPN) plasma levels are highly prognostic in advanced non-small cell lung cancer (NSCLC): Analysis of SWOG S0003. PC Mack, MW Redman, K Chansky, SK Williamson, N Farneth, PN Lara, Q Le, PH Gumerlock, JJ Crowley, DR Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 24(18S):#7198, 2006. S0339 (2242) 11/15/00 11/15/02 Bortezomib + gemcitabine (Gem)/carboplatin (Carbo) results Lung in encouraging survival in advanced non-small cell lung cancer (NSCLC): results of a phase II Southwest Oncology Group (SWOG) trial (S0339). AM Davies, J McCoy, PN Lara, PH Gumerlock, J Crowley, DR Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 24 (18S):#7017, 2006. 1/15/04 10/1/04 S0342 (2230) Concurrent chemotherapy plus cetuximab or chemotherapy Lung followed by cetuximab in advanced non-small cell lung cancer (NSCLC): a randomized phase II selectional trial SWOG 0342. K Kelly, RS Herbst, JJ Crowley, J McCoy, JN Atkins, PN Lara, SR Dakhil, KS Albain, ES Kim, DR Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 24(18S):#7015, 2006. 7/1/04 8/1/05 Multiple Studies (2232) Alternative measures predicting clinical benefit in advanced Lung non-small cell lung cancer (NSCLC) from Southwest Oncology Group (SWOG) randomized trials: implications for clinical trial design. PN Lara Jr, MW Redman, K Kelly, MJ Edelman, SK Williamson, JJ Crowley, DR Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 24(18S):#7006, 2006. *Presented Lung SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 2005 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED S9714 (2076) Advanced bronchioloalveolar carcinoma: a phase II trial of Lung paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. HL West, JJ Crowley, RB Vance, WA Franklin, RB Livingston, SR Dakhil, JK Giguere, SE Rivkin, MJ Kraut, DR Gandara. Annals of Oncology 16:1076-1080, 2005. 5/15/97 3/15/00 S0003 (2188) Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell-lung cancer: Southwest Oncology Group trial S0003. SK Williamson, JJ Crowley, PN Lara Jr, J McCoy, DHM Lau, RW Tucker, GM Mills, DR Gandara. Journal of Clinical Oncology 23(36):9097-9104, 2005. Lung 11/15/00 11/15/02 S0126 (2183) Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group study. FR Hirsch, M Varella-Garcia, J McCoy, H West, AC Xavier, P Gumerlock, PA Bunn Jr, WA Franklin, J Crowley, DR Gandara. Journal of Clinical Oncology 23(28):6838-6845, 2005. Lung Correlative 12/1/01 7/1/03 JBR10 (2214) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. T Winton, R Livingston, D Johnson, J Rigas, M Johnston, C Butts, Y Cormier, G Goss, R Inculet, E Vallieres, W Fry, D Bethune, J Ayoub, K Ding, L Seymour, B Graham, MS Tsao, D Gandara, K Kesler, T Demmy, F Shepherd. New England Journal of Medicine 352(25):2589-2597, 2005. Lung 12/1/96 4/30/01 Multiple Studies (2191) Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. LE Gaspar, K Chansky, KS Albain, E Vallieres, V Rusch, JJ Crowley, RB Livingston, DR Gandara. Journal of Clinical Oncology 23(13):2955-2961, 2005. Lung Multiple Studies (2386) Southwest Oncology Group: Two decades of experience in non-small cell lung cancer. AT Turrisi, J Crowley, K Albain, L Gaspar, D Gandara. Seminars in Oncology 32(2Suppl3):S119-S121, 2005. Lung Multiple Studies (2461) Therapeutic strategies for combined-modality therapy of locally advanced non-small cell lung cancer: rationale for consolidation docetaxel therapy. DR Gandara, E Vallieres, Lung LE Gaspar, K Kelly, KS Albain, RS Herbst Jr, PN Lara Jr, P Mack, PH Gumerlock, JJ Crowley. Clinical Lung Cancer 7 Suppl 3:S93-97, 2005. PMID: 16384543 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ ABSTRACTS PUBLISHED/PRESENTED S9900 (2295) S9900: Preliminary “surgical” results of a phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC). E Vallieres, KMW Pisters, J Crowely, K Chansky, P Bunn, D Gandara. Lung Cancer 49 (Suppl 2):S43 (0-124), 2005. *9336 (2201) Lung 10/15/99 7/15/04 Phase III study of concurrent chemotherapy and radiotherapy Lung (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). KS Albain, RS Swann, VR Rusch, AT Turrisi, FA Shepherd, CJ Smith, DR Gandara, DH Johnson, MR Green, RC Miller. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 23(16S):624s (#7014), 2005. 5/15/94 11/30/01 *9504 (2154) Long term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504). DR Gandara, K Chansky, LE Gaspar, KS Albain, PN Lara, J Crowley. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 23(16S):635S (#7059), 2005. Lung 10/15/96 12/1/98 *S9900 (2182) S9900: a phase III trial of surgery alone or surgery plus Lung preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results. K Pisters, E Vallieres, P Bunn, J Crowley, R Ginsberg, P Ellis, B Meyers, R Marks, J Treat, D Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 23(16S):624S (#LBA7012), 2005. 10/15/99 7/15/04 *S0023 (2202) Low incidence of pneumonitis on SWOG 0023: a preliminary Lung analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and gefitinib/ placebo maintenance in patients with inoperable stage III non-small cell lung cancer. K Kelly, LE Gaspar, K Chansky, KS Albain, J Crowley, DR Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 23(16S):634s (#7058), 2005. 6/15/01 4/15/05 *S0126 (2159) Increased EGFR gene copy number detected by fish is Lung associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126). FR Hirsch, DR Gandara, J McCoy, J Crowley, HJ West, PH Gumerlock, PA Bunn , WA Franklin, M Varella-Garcia. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 23(16S):628s (#7030), 2005. 12/1/01 7/1/03 *S0126 (2199) Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib. PH Gumerlock, WS 12/1/01 7/1/03 Lung _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ Holland, H Chen, WA Franklin, FR Hirsch, PC Mack, AM Davies, J McCoy, HJ West, DR Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 23(16S):623s (#7008), 2005. *S0327 (2160) *Presented The proteasome inhibitor PS-341(bortezemib) in platinum Lung (plat)-treated extensive-stage small cell lung cancer (E-SCLC): a SWOG (0327) phase II trial. J Johl, K Chansky, PN Lara, AM Davies, R Bold, DR Gandara. Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 23(16S):632s (#7047), 2005. 9/1/03 9/15/04 SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 2004 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED S9713 (2029) Phase II trial of cisplatin/etoposide and concurrent Lung radiotherapy followed by paclitaxel/carboplatin consolidation for limited small cell lung cancer. Southwest Oncology Group 9713. MJ Edelman, K Chansky, LE Gaspar, B Leigh, GR Weiss, SA Taylor, J Crowley, R Livingston, DR Gandara. Journal of Clinical Oncology 22(1):127-132, 2004. 7/1/98 8/1/99 S9714/0126 (2085) Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. DR Gandara, H West, K Chansky, AM Davies, DHM Lau, J Crowley, PH Gumerlock, FR Hirsh, WA Franklin. Clinical Cancer Research 10 (Suppl):4205s-4209s, 2004. Lung S9806 (2030) Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. MJ Edelman, JI Clark, K Chansky, K Albain, N Bhoopalam, GR Weiss, JK Giguere, K Kelly, J Crowley, DR Gandara. Clinical Cancer Research 10:5022-5026, 2004. Lung 11/1/98 11/15/99 S0004 (2071) Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited stage small cell lung cancer (S0004): a Southwest Oncology Group study. QT Le, J McCoy, S Williamson, J Ryu, LE Gaspar, M Edelman, S Dakhil, SD Sides, JJ Crowley, DR Gandara. Clinical Cancer Research 10:5418-5424, 2004. Lung 10/15/00 4/1/02 Multiple Studies (2176) Mutant DNA in plasma of lung cancer patients; potential for monitoring response to therapy. T Kimura, WS Holland, T Kawaguchi, SK Williamson, K Chansky, JJ Crowley, JH Doroshow, HJ Lenz, DR Gandara, PH Gumerlock. Annals of the New York Academy of Sciences 1022: 55-60, 2004. Lung ABSTRACTS PUBLISHED/PRESENTED *9252 (2053) EGFr dinucleotide repeat polymorphism in non-small cell lung Lung cancer. S Dubey, J Miller, P Stephenson, SM Keller, DH Johnson, JH Schiller, JM Kolesar. Proc of the American Society of Clinical Oncology 23:852 (#9585), 2004. 3/1/94 12/1/96 S0003 (2099) Hypoxia-related markers in the plasma of patients with advanced non-small cell lung cancer (NSCLC) and survival from chemotherapy: Southwest Oncology Group (SWOG) S0003. IV Galvin, PN Lara, Q Le, K Chansky, JJ Crowley, S Williamson, DR Gandara, PH Gumerlock. Proc of the American Society of Clinical Oncology 23:649 (#7146), 2004. 11/15/00 11/15/02 Lung _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ *S0003 (2055) Japan-SWOG common arm analysis of paclitaxel/carboplatin Lung in advanced stage non-small cell lung cancer (NSCLC): a model for prospective comparison of cooperative group trials. DR Gandara, Y Ohe, K Kubota, Y Nishiwaki, Y Ariyoshi, N Saijo, S Williamson, PN Lara, J Crowley, M Fukuoka. Proc of the American Society of Clinical Oncology 23:616 (#7007), 2004. 11/15/00 11/15/02 *S0027 (2058) Sequential vinorelbine (V) and docetaxel (D) in advanced Lung non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: a SWOG phase II trial (S0027). PJ Hesketh, K Chansky, DH Lau, J Crowley, DR Gandara. Proc of the American Society of Clinical Oncology 23:627 (#7056), 2004. 9/1/01 7/1/03 S0119 (2098) SWOG S0119: a phase II study of gemcitabine and irinotecan Lung for patients with untreated extensive stage small cell lung cancer (SCLC). WL Akerley, J McCoy, P Hesketh, J Crowley, L Kaye, D Gandara. Proc of the American Society of Clinical Oncology 23:663 (#7202), 2004. 1/1/02 2/15/03 *S0126 (2062) Gefitinib (ZD1839) therapy for advanced bronchioloalveolar Lung lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126. H West, WA Franklin, PH Gumerlock, RB Vance, DHM Lau, J McCoy, J Crowley, DR Gandara. Proc of the American Society of Clinical Oncology 23:618 (#7014), 2004. 12/1/01 7/1/03 *Presented SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 2003 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 9504 (1833) Consolidation docetaxel after concurrent chemoradioLung therapy in stage IIIB non-small cell lung cancer: Phase II Southwest Oncology Group study S9504. DR Gandara, K Chansky, KS Albain, BR Leigh, LE Gaspar, PN Lara Jr, H Burris, P Gumerlock, JP Kuebler, JD Bearden III, J Crowley, R Livingston. Journal of Clinical Oncology 21(10):2004-2010, 2003. 10/15/96 12/1/98 ABSTRACTS PUBLISHED/PRESENTED *9252 (1880) Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIa non-small cell lung cancer (NSCLC) leads to higher than expected risk of death from intercurrent disease (DID). HA Wakelee, P Stephenson, SM Keller, H Wagner, A Herskovic, R Komaki, RS Marks, MC Perry, RB Livingston, DH Johnson. Proc of the American Society of Clinical Oncology 22:633 (#2545), 2003. Lung 3/1/94 12/1/96 *9336 (1874) Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09). KS Albain, CB Scott, VR Rusch, AT Turrisi, FA Shepherd, C Smith, DR Gandara, DH Johnson, MR Green, RC Miller. Proc of the American Society of Clinical Oncology 22:621 (#2497), 2003. Lung 5/15/94 11/30/01 9416 (2035) Induction chemoradiotherapy and surgical resection for non-small cell lung carcinomas of the superior sulcus (pancoast tumors): mature results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). VW Rusch, D Giroux, MJ Kraut, J Crowley, M Hazuka, DH Johnson, L Shulman, F Shepherd, D Deschamps, DR Gandara. Proc of the American Society of Clinical Oncology 22:634 (#2548), 2003. Lung 4/15/95 8/1/99 9509 (1995) Molecular abnormalities of DNA damage and antimicrotubule response pathways in non-small cell lung carcinomas (NSCLC) from patients on the Southwest Oncology Group (SWOG) 9509 trial. PC Mack, IV Galvin, T Kimura, WA Franklin, KD Danenberg, K Chansky, WS Holland, JJ Crowley, DR Gandara, PH Gumerlock. Proc of the American Society of Clinical Oncology 22:639 (#2569), 2003. Lung 4/1/96 1/1/98 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ *S9714 (1889) EGFR, HER2 and ERB-B pathway activation in bronchioloalveolar carcinoma (BAC): analysis of SWOG 9417 and lung SPORE tissue samples. WA Franklin, PH Gumerlock, J Crowley, K Chansky, HJ West, DR Gandara. Proc of the American Society of Clinical Oncology 22:620 (#2493), 2003. Lung 5/15/97 3/15/00 S0003 (1994) Hypoxia-induced proteins in plasma of patients on the Southwest Oncology Group (SWOG) S0003 trial in advanced non-small cell lung carcinoma (NSCLC). IV Galvin, PN Lara, Q Le, K Chansky, J McCoy, JJ Crowley, DR Gandara, PH Gumerlock. Proc of the American Society of Clinical Oncology 22:667 (#2682), 2003. Lung 11/15/00 11/15/02 S0003 (2001) S0003: Paclitaxel/carboplatin (PC) versus PC + tirapazamine Lung (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III Southwest Oncology Group (SWOG) trial. SK Williamson, JJ Crowley, PN Lara, RW Tucker, J McCoy, DH Lau, DR Gandara. Lung Cancer 41(Suppl 2):S29 (#O-89), 2003. 11/15/00 11/15/02 *S0003 (1876) S0003: Paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III Southwest Oncology Group (SWOG) trial. SK Williamson, JJ Crowley, PN Lara, RW Tucker, J McCoy, DHM Lau, DR Gandara. Proc of the American Society of Clinical Oncology 22:622 (#2502), 2003. Lung 11/15/00 11/15/02 *JRB10 (1881) Compliance with adjuvant chemotherapy (ACT) in non-small lung cancer (NSCLC): NCIC CTG BR.10/ JBR.10. N Alam, F Shepherd, T Winton, B Graham, D Johnson, R Livingston, J Rigas, M Whitehead, K Ding, L Seymour. Proc of the American Society of Clinical Oncology 22:633 (#2547), 2003. Lung 1/21/96 4/30/01 *Multiple Studies (1883) Time from treatment to subsequent diagnosis of brain metastases in Stage III non-small cell lung cancer (NSCLC): a retrospective review by the Southwest Oncology Group (SWOG). LE Gaspar, K Chansky, KS Albain, E Vallieres, V Rusch, J Crowley, DR Gandara. Proc of the American Society of Clinical Oncology 22:636 (#2558), 2003. Lung *Presented SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 2002 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 8300 (1947) Factorial design considerations. S Green, PY Liu, J O’Sullivan. Journal of Clinical Oncology 20(16): 3424-3430, 2002. Lung 7/20/84 3/1/88 9019 (1743) Concurrent cisplatin, etoposide and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG-9019. KS Albain, JJ Crowley, AT Turrisi, III, DR Gandara, WB Farrar, JI Clark, KR Beasley, RB Livingston. Journal of Clinical Oncology 20(16):3454-3460, 2002. Lung 4/15/92 12/1/95 9252 (1921) The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. SM Keller, MG Vangel, S Adak, H Wagner, JH Schiller, A Herskovic, R Komaki, MC Perry, RS Marks, RB Livingston, DH Johnson. Lung Cancer 37:303-309, 2002. Lung 3/1/94 12/1/96 9509 (1702) Economic analysis of vinorelbine plus cisplatin versus Lung paclitaxel plus carboplatin for advanced non-small-cell lung cancer. SD Ramsey, CM Moinpour, LC Lovato, JJ Crowley, P Grevstad, CA Presant, SE Rivkin, K Kelly, DR Gandara. Journal of the National Cancer Institute 94(4):291-297, 2002. 4/1/96 1/1/98 9509 (1703) Quality of life in advanced non-small-cell lung cancer: results Lung of a Southwest Oncology Group randomized trial. CM Moinpour, B Lyons, PK Grevstad, LC Lovato, J Crowley, K Czaplicki, ZM Buckner, PA Ganz, K Kelly, DR Gandara. Quality of Life Research 11:115-126, 2002. 4/1/96 1/1/98 9509 (1858) Tests for lifetime utility or cost via calibrating survival time. Y Huang, L Lovato. Statistica Sinica 12:707-723, 2002. 4/1/96 1/1/98 Lung ABSTRACTS PUBLISHED/PRESENTED S9712 (1794) Concurrent carboplatin/etoposide and radiation followed by Lung paclitaxel consolidation for poor risk stage III non-small cell lung cancer: a Southwest Oncology Group (SWOG) phase II trial (S9712). AM Davies, DH Lau, J Crowley, B Leigh, D Gandara. Proc of the American Society of Clinical Oncology 21:298a (#1191), 2002. 2/15/98 6/1/00 S9713 (1795) Phase II (SWOG 9713) trial of cisplatin/etoposide (PE) and concurrent radiotherapy (XRT) followed by paclitaxel/carboplatin (TC) consolidation for limited small cell lung cancer 7/1/98 8/1/99 Lung _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ (LSCLC). MJ Edelman, K Chansky, B Leigh, J Crowley, DR Gandara. Proc of the American Society of Clinical Oncology 21:303a (#1210), 2002. S9914 (1797) Southwest Oncology Group trial (SWOG) 9914: phase II trial Lung of paclitaxel, carboplatin and topotecan (PCT) in untreated patients (pts) with extensive small cell lung cancer (SCLC). F Dunphy, P Hesketh, K Chansky, DR Gandara. Proc of the American Society of Clinical Oncology 21:297a (#1184), 2002. 10/15/99 6/15/01 S0004 (1799) SWOG 0004 - pilot study of tirapazamine (TPZ) plus cisplatin/etoposide (PE) and concurrent thoracic radiotherapy (RT) in limited small cell lung cancer (LSCLC). Q-T Le, K Chansky, SK Williamson, MJ Edelman, J Ryu, LE Gaspar, J Crowley, DR Gandara. Proc of the American Society of Clinical Oncology 21:294a (#1174), 2002. Lung 10/15/00 8/15/01 C9732 (1834) Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC). HB Niell, JE Herndon, AA Miller, DM Watson, A Sandler, K Kelly, R Marks, MR Green. Proc of the American Society of Clinical Oncology 21:293a (#1169), 2002. Lung 8/15/99 7/13/01 Multiple Studies (1970) Analysis of prognostic factors in Southwest Oncology Group stage III non-small cell lung cancer trials requiring pretreatment histological assessment of mediastinal lymph nodes. CR Thomas Jr, K Chansky, KS Albain, MJ Kraut, VW Rusch, RB Livingston, JC Crowley, DR Gandara. Int J of Radiat Oncol Biol Phys 54(2):103-104 (#174), 2002. Lung *Presented SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 2001 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 8269 (1661) Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer. CR Thomas Jr, DJ Giroux, LM Janaki, AT Turrisi, JJ Crowley, SA Taylor, JD McCracken, PGS Giri, W Gordon Jr, RB Livingston, DR Gandara. Lung Cancer 33:213-219, 2001. Lung 8/11/82 3/20/86 9221 (1712) Randomized phase-III Intergroup trial of isotretinoin to Lung prevent second primary tumors in stage-1 non-small-cell lung cancer. SM Lippman, JJ Lee, DD Karp, EE Vokes, SE Benner, GE Goodman, FR Khuri, R Marks, RJ Winn, W Fry, SL Graziano, DR Gandara, G Okawara, CL Woodhouse, B Williams, C Perez, HW Kim, R Lotan, JA Roth, WK Hong. Journal of the National Cancer Institute 93(8):605-618, 2001. 3/15/93 4/9/97 9323 (1637) Lack of prognostic significance of p53 and K-ras mutations Lung in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. JH Schiller, S Adak, RH Feins, SM Keller, WA Fry, RB Livingston, MEM Hammond, B Wolf, L Sabatini, J Jett, L Kohman, DH Johnson. Journal of Clinical Oncology 19(2):448-457, 2001. 3/1/94 12/1/96 9416 (1695) Induction chemoradiation and surgical resection for non-small Lung cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). VW Rusch, DJ Giroux, MJ Kraut, J Crowley, M Hazuka, D Johnson, M Goldberg, F Detterbeck, F Shepherd, R Burkes, T Winton, C Deschamps, R Livingston, D Gandara. The Journal of Thoracic and Cardiovascular Surgery 121(3):472-483, 2001. 4/15/95 8/1/99 9449 (1752) Combined etoposide, ifosfamide and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an Intergroup trial. PJ Loehrer Sr, M Jiroutek, S Aisner, J Aisner, M Green, CR Thomas Jr, R Livingston, DH Johnson. Cancer 91(11):2010-2015, 2001. Lung 9/1/95 2/27/97 9509 (1701) Randomized phase III trial of paclitaxel plus carboplatin Lung versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. K Kelly, J Crowley, PA Bunn, CA Presant, PK Grevstad, CM Moinpour, SD Ramsey, AJ Wozniak, GR Weiss, DF Moore, VK Israel, RB Livingston, DR Gandara. Journal of Clinical Oncology 19(13):3210-3218, 2001. 4/1/96 1/1/98 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ Multiple Studies (1942) Factorial designs with time to event end points. S Green. In: Handbook of Statistics in Clinical Oncology J Crowley, ed. Marcel-Dekker, New York, 161-171, 2001. Lung ABSTRACTS PUBLISHED/PRESENTED 9308/9509 (1731) Should older patients (Pts) receive combination chemoLung therapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology trials 9509 and 9308. K Kelly, S Giarritta, W Akerley, P Hesketh, A Wozniak, K Albain, J Crowley, DR Gandara. Proc of the American Society of Clinical Oncology 20:329a (#1313), 2001. *9504 (1735) Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIb non-small cell lung cancer (NSCLC) (SWOG 9504): patterns of failure and updated survival. L Gaspar, D Gandara, K Chansky, KS Albain, PN Lara Jr., J Crowley, RB Livingston. Proc of the American Society of Clinical Oncology 20:315a (#1255), 2001 Lung 10/15/96 12/1/98 S9705 (1664) Cisplatin, etoposide, and paclitaxel with granulocyte colonystimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group 1,2 . K Kelly, PA Bunn Jr, L Lovato, JJ Lung 8/15/97 7/1/98 S9714 (1726) A phase II Southwest Oncology Group trial (S9714) utilizing Lung paclitaxel by 96-hour infusion in stage IIIb and IV bronchioloalveolar carcinoma of the lung (BAC). RB Vance, JC Crowley, RB Livingston, DR Gandara. Proc of the American Society of Clinical Oncology 20:336a (#1340), 2001. 5/15/97 3/15/00 *S9718 (1716) Southwest Oncology Group trial (SWOG) S9718: a phase II study of gemcitabine plus cisplatin in patients with extensive small cell lung cancer (E-SCLC). VP Israel, K Chansky, D Gandara. Proc of the American Society of Clinical Oncology 20:316a (#1262), 2001. Lung 7/1/98 6/15/99 *S9806 (1722) Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine (CARB/G) followed by paclitaxel (P) or cisplatin/vinorelbine (C/V) followed by docetaxel (D). MJ Edelman, JI Clark, K Chansky, J Crowley, K Albain, DR Gandara. Proc of the American Society of Clinical Oncology 20:314a (#1254), 2001. Lung 1/1/98 11/15/99 Crowley, RB Livingston, DR Gandara. Clinical Cancer Research 7:2325-2329, 2001. *Presented SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 2000 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 8992 (1649) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. W Sause, P Kolesar, S Taylor, D Johnson, R Livingston, R Komaki, B Emami, W Curran, Jr, R Byhardt, A Rashid Dar, A Turrisi. Chest 117:358-364, 2000. Lung 6/15/90 2/1/92 9252 (1713) A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA nonsmall-cell lung cancer. SM Keller, S Adak, H Wagner, A Herskovic, R Komaki, BJ Brooks, MC Perry RB Livingston, DH Johnson. New England Journal of Medicine 343(17):1217-1222, 2000. Lung 3/1/94 12/1/96 Multiple Studies (1709) Evolution of combined modality therapy for stage III nonsmall-cell lung cancer. DR Gandara, M Edelman, P Lara, P Roberts, B Leigh. Oncology 14(7), Suppl 5:35-41, 2000. Lung ABSTRACTS PUBLISHED/PRESENTED 8269 (1643) Ten-year follow-up of SWOG 8269: a phase 2 trial of concomitant cisplatin-etoposide (PE) and daily thoracic radiotherapy (TRT) in limited small cell lung cancer (L-SCLC). CR Thomas, FJ Giroux, LM Janaki, AT Turrisi, JJ Crowley, JD McCracken, RB Livingston, DR Gandara. Radiology 217 Suppl:261 (#251), 2000. Lung 12/1/82 3/20/86 *9416 (1609) Induction chemoradiation plus surgical resection is feasible Lung and highly effective treatment for Pancoast tumors: Initial results of SWOG 9416 (Intergroup 0160) trial. MJ Kraut, VW Rusch, JJ Crowley, DR Gandara. Proc of the American Society of Clinical Oncology 19:487a (#1906), 2000. 4/15/95 8/1/99 9504 (1911) Pathologic stage IIIb non-small cell lung cancer (NSCLC): prolonged survival with consolidation docetaxel following concurrent chemoradiotherapy. DR Gandara, LC Lovato, KS Albain, B Leigh, PN Lara JR, JJ Crowley, RB Livingston. Lung Cancer 29(Suppl 2):92 (#302), 2000. Lung 10/15/96 12/1/98 *9504 (1604) Prolonged survival in pathologic stage IIIb non-small cell Lung lung cancer (NSCLC) with concurrent chemoradiotherapy followed by consolidation docetaxel: a phase II study (S9504) of the Southwest Oncology Group (SWOG). DR Gandara, LC Lovato, KS Albain, B Leigh, PN Lara Jr, JJ Crowley, K Stelzer, RB Livingston. Proc of the American Society of Clinical Oncology 10/15/96 12/1/98 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ 19:490a (#1916), 2000. 9509 (1912) An economic analysis alongside a prospective randomized Lung multicenter clinical trial of cisplatin/vinorelbine vs. carboplatin/paclitaxel for advanced non small cell lung cancer. SD Ramsey, CM Moinpour, LC Lovato, PK Grevstad, C Presant, D Gandara, K Kelly. Lung Cancer 29(Suppl 2): 4 (#5), 2000. 4/1/96 1/1/98 *9509 (1605) An economic analysis of Southwest Oncology Group trial S9509: Cisplatin/vinorelbine vs. carboplatin/paclitaxel for advanced nonsmall cell lung cancer. SD Ramsey, CM Moinpour, LC Lovato, PK Grevstad, K Kelly, C Presant. Proc of the American Society of Clinical Oncology 19:489a (#1913), 2000. Lung 4/1/96 1/1/98 S9705 (1913) A phase II study of cisplatin, etoposide, and paclitaxel (PET) with G-CSF in untreated patients with extensive small cell lung cancer: a Southwest Oncology Group trial. K Kelly, PA Bunn, L Lovato, J Crowley, RB Livingston, DR Gandara. Lung Cancer 29(Suppl 2):8 (#20), 2000. Lung 8/15/97 7/1/98 *S9705 (1603) Final results from Southwest Oncology Group trial (SWOG) Lung 9705: a phase II trial of cisplatin, etoposide, and paclitaxel (PET) with G-CSF in untreated patients (Pts) with extensive stage small cell lung (SCLC). K Kelly, PA Bunn Jr, L Lovato, J Crowley, RB Livingston, DR Gandara. Proc of the American Society of Clinical Oncology 19:492a (#1923), 2000. 8/15/97 7/1/98 S9714 (1648) Phase II evaluation of paclitaxel by 96-hour infusion in stage IIIb and IV bronchioloalveolar carcinoma (BAC). RB Vance, JJ Crowley, D Gandara. Lung Cancer 29(Suppl 2):7 (#16), 2000. Lung 5/15/97 3/15/00 Multiple Studies (1909) Comparison of quality of life (QLI) outcomes for two chemotherapy regimens in non-small cell lung cancer (NSCLC). CM Moinpour, B Lyons, LC Lovato, PK Grevstad, K Kelly, J Crowley, D Gandara. Lung Cancer 29(Suppl 2):34 (#109), 2000. Lung Multiple Studies (1971) Current status of therapy for advanced non-small cell lung cancer: a perspective from the Southwest Oncology Group (SWOG). DR Gandara, K Kelly, P Gumerlock, J Crowley. Lung Cancer 29(Suppl 2):186, 2000. Lung Multiple Studies (1972) Gemcitabine and platinum combinations in advanced non-small cell lung cancer: an update. DR Gandara, MJ Edelman, P Lara, D Lau. Lung Cancer 29(Suppl 2):7, 2000. Lung *Multiple Studies Phase III trials in patients with advanced stage non-small lung cancer (NSCLC) from 1973-1994. BE Johnson, B Freidlin, B Conley, MR Green, DJ Johnson, DR Gandara, Lung _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MJ O’Connell, R Simon, OS Breathnach. Proc of the American Society of Clinical Oncology 19:488a (#1909), 2000. Multiple Studies (1908) Phase III trials in patients with advanced stage non-small cell lung cancer: the experience in North America from 1973-1994. OS Breathnach, B Freidlin, B Conlay, MR Green, DJ Johnson, DR Gandara, M O’Connell, R Simon, BE Johnson. Lung Cancer 29(Suppl 2):20 (#62), 2000. Lung Multiple Studies (1910) Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC): review of the Southwest Oncology Group (SWOG) database. W Akerley, J Crowley, D Giroux, D Gandara. Lung Cancer 29(Suppl 2):33 (#106), 2000. Lung *Presented SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1999 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 8991 (1422) Twice-daily compared with once daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. AT Turrisi, KM Kim, R Blum, WT Sause, RB Livingston, R Komaki, H Wagner, S Aisner, DH Johnson. New England Journal of Medicine 340(4):265-271, 1999. Lung 2/15/90 8/1/92 9216 (1500) Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. N Murray, RB Livingston, FA Shepherd, K James, B Zee, A Langleben, M Kraut, J Bearden, JW Goodwin, C Grafton, A Turrisi, D Walde, H Croft, D Osoba, J Ottaway, D Gandara. Journal of Clinical Oncology 17(8):2300-2308, 1999. Lung 12/15/92 4/26/96 9242 (1490) Evaluation of docetaxel in previously untreated extensive stage small cell lung cancer: A Southwest Oncology Group phase II trial. PJ Hesketh, JJ Crowley, HA Burris, SK Williamson, SP Balcerzak, DM Peereboom, JW Goodwin, HM Gross, DF Moore, RB Livingston, DR Gandara. Cancer Journal from Scientific American 5(4):237-241, 1999. Lung 5/1/93 1/15/97 9307 (1416) Treatment of poor prognosis extensive disease small cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide – A Southwest Oncology Group clinical and pharmacokinetic study. SM Grunberg, JJ Crowley, KR Hande, D Giroux, NC Munshi, DHM Lau, LE Schroder, MH Zangmeister, SP Balcerzak, HE Hynes, DR Gandara. Cancer Chemotherapy and Pharmacology 44:461-468, 1999. Lung 7/1/93 6/1/96 Multiple Studies (1568) Current status of chemotherapy for advanced non-small cell lung cancer: a perspective from the Southwest Oncology Group (SWOG). DR Gandara, MJ Edelman, J Crowley. Revista de Oncologia 1(Suppl 2):17-19, 1999 Lung Multiple Studies (1569) Preoperative chemotherapy in stage III non-small cell lung cancer: long-term outcome. DR Gandara, B Leigh, E Vallieres, KS Albain. Lung Cancer 26:3-6, 1999. Lung None (1530) Summary of the proceedings of the United States - Japan lung cancer clinical trials summit: San Francisco, California, 20-22 November, 1998. BR Leigh, DR Gandara JJ Crowley, K Furuse, RB Livingston, M Fukushima, CA Coltman Jr. Lung Cancer 24:181-191, 1999. Lung _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ ABSTRACTS PUBLISHED/PRESENTED *8805 (1499) Long-term survival after concurrent cisplatin/etoposide (PE) plus chest radiotherapy (RT) followed by surgery in bulky, stages IIIA(N2) and IIIB non-small cell lung cancer (NSCLC): 6-year outcomes from Southwest Oncology Group study 8805. K Albain, V Rusch, J Crowley, T Rice, A Turrisi, J Weick, V Lonchyna, C Presant, R McKenna, D Gandara, H Fosmire, S Taylor, K Stelzer, K Beasley, R Livingston. Proc of the American Society of Clinical Oncology 18:467a (#1801), 1999. Lung 7/1/88 3/15/92 *9252 E3590 (1533) Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: an Intergroup trial (E3590). SM Keller, S Adak, H Wagner, A Herskovic, BJ Brooks, MC Perry, RB Livingston, DH Johnson. Proc of the American Society of Clinical Oncology 18:465a (#1793), 1999. Lung 3/1/94 12/1/96 *9323 (1510) Prognostic significance of p53 and K-RAS mutations in primary resected non-small cell lung cancer: Preliminary results from prospective randomized trial of postoperative adjuvant therapy (intergroup trial 0115). JH Schiller, S Adak, R Feins, S Keller, W Fry, R Livingston, B Wolf, J Jett, L Kohman, D Johnson. Proc of the American Society of Clinical Oncology 18:464a (#1789), 1999. Lung 3/1/94 12/1/96 *9509 (1505) A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial. K Kelly, J Crowley, BA Bunn, RB Livingston, DR Gandara. Proc of the American Society of Clinical Oncology 18:461a (#1777), 1999. Lung 4/1/96 1/1/98 *9705 (1504) Preliminary toxicity results from Southwest Oncology Group Lung trial (SWOG) 9705: A phase II trial of cisplatin, etoposide and paclitaxel (PET) with G-CSF in untreated patients (PTS) with extensive small cell lung cancer (SCLC). PA Bunn, K Kelly, J Crowley, RB Livingston, DR Gandara. Proc of the American Society of Clinical Oncology 18:468a (#1807), 1999. 8/15/97 7/1/98 *Presented SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1998 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED 8300 (1105) A randomized trial of chemotherapy and radiotherapy for stage III non-small cell lung cancer. TP Miller, JJ Crowley, J Mira, JG Schwartz, L Hutchins, L Baker, R Natale, EM Chase, RB Livingston. Cancer Therapeutics 1(4):229-236, 1998. Lung 7/20/84 3/1/88 9229 (1331) Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: A phase II study of the Southwest Oncology Group (SWOG-9229). CR Thomas Jr, DJ Giroux, KJ Stelzer, JB Craig, LR Laufman, SA Taylor, JW Goodwin, JJ Crowley, RB Livingston. International Journal of Radiation Oncology, Biology, Physics 40(5): 1039-1047, 1998. Lung 2/15/93 5/1/94 9308 (1323) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. AJ Wozniak, JJ Crowley, SP Balcerzak, GR Weiss, CH Spiridonidis, LH Baker, KS Albain, K Kelly, SA Taylor, DR Gandara, RB Livingston. Journal of Clinical Oncology 16(7):2459-2465, 1998. Lung 10/15/93 6/1/95 9429 (1384) Southwest Oncology Group phase II trial of concurrent Lung carboplatin, etoposide and radiation for poor-risk stage III non-small cell lung cancer. DH Lau, JJ Crowley, DR Gandara, MB Hazuka, KS Albain, B Leigh, WS Fletcher, KS Lanier, LW Keiser, RB Livingston. Journal of Clinical Oncology 16(9):3078-3081, 1998. 8/15/94 9/1/95 Statistical Paper (1929) Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology economics workbook. M Brown, HA Glick, F Harrell, J Herndon, M McCabe, C Moinpour, KA Schulman, T Smith, J Weeks, DM Seils. Journal of the National Cancer Institute Monographs No.24:1-28, 1998. Lung Multiple Studies (1570) Small cell lung cancer: current status of new chemotherapeutic agents. JM Edelman, DR Gandara. Critical Reviews in Oncology/Hematology 27:211-220, 1998. Lung _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ ABSTRACTS PUBLISHED/PRESENTED *8991 (1420) Observations after 5 year follow-up of intergroup trial 0096: 4 cycles of cisplatin(P) etoposide (E) and concurrent 45 GY thoracic radiotherapy (TRT) given in daily (QD) or twice-daily fractions followed by 25 GY PCI. Survival differences and patterns of failure. A Turrisi, K Kim, W Sause, R Komaki, H Wagner, S Aisner, R Livingston, R Blum, D Johnson. Proc of the American Society of Clinical Oncology 17:457a (#1757), 1998. Lung 2/15/90 8/1/92 *8991 (1421) Incidence and clinical significance of variant morphology Lung (small cell/large cell subtype) in limited stage small cell lung cancer (SCLC). A prospective analysis of an intergroup ECOG, RTOG and SWOG study. SC Aisner, A Turrisi, KM Kim, WT Sause, RB Livingston, L Einhorn, H Wagner, D Ettinger, R Komaki, R Blum, DH Johnson. Proc of the American Society of Clinical Oncology 17:458a (#1764), 1998. 2/15/90 8/1/92 *9221 (1410) Phase III intergroup trial of 13-cis-retinoic acid to prevent Lung second primary tumors in stage-I non-small cell lung cancer (NSCLC): Interim report of NCI #191-0001. SM Lippman, JJ Lee, DD Karp, EE Vokes, SE Benner, GE Goodman, C Kardinal, RJ Winn, JA Roth, WK Hong. Proc of the American Society of Clinical Oncology 17:456a (#1753), 1998. 3/15/93 4/9/97 *9242 (1375) Docetaxel (taxotere) in extensive stage small cell lung cancer (SCLC): A phase II trial of the Southwest Oncology Group (SWOG). HA Burris, JJ Crowley, SK Williamson, DR Gandara, RB Livingston. Proc of the American Society of Clinical Oncology 17:451a (#1737), 1998. 5/1/93 1/15/97 *9308 (1376) Randomized phase III trial of cisplatin (CDDP) vs CDDP Lung plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): An update of a Southwest Oncology Group study (SWOG-9308). AJ Wozniak, JJ Crowley, SP Balcerzak, GR Weiss, CH Spiridonidis, LH Baker, KS Albain, K Kelly, SA Taylor, DR Gandara, RB Livingston. Proc of the American Society of Clinical Oncology 17:453a (#1744), 1998. 10/15/93 6/1/95 9449 (1423) Phase II trial of etoposide (V), ifosfamide (I) plus cisplatin Lung (P) in patients with advanced thymoma (T) or thymic carcinoma (TC): Preliminary results from an ECOG coordinated intergroup trial. PJ Loehrer, M Jiroutek, S Aisner, J Aisner, MR Greene, CR Thomas Jr, RB Livingston, DH Johnson. Proc of the American Society of Clinical Oncology 17:30a (#118), 1998. 9/1/95 2/27/97 *Presented Lung SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1997 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED 8241 (1329) A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: A Southwest Oncology Group study. JK Weick, J Crowley, RB Natale, BL Hom, S Rivkin, CA Coltman Jr, SA Taylor, RB Livingston. Classic Papers and Current Comments 2(1):172-177, 1997. 8609 (667) Lung 12/23/83 11/01/84 Teniposide (VM-26) as a single drug treatment for patients Lung with extensive small cell lung carcinoma. A phase II study of the Southwest Oncology Group. PN Grozea, JJ Crowley, VA Canfield, L Kingsbury, SW Ross, GS Beltran, LR Laufman, GR Weiss, RB Livingston. Cancer 80(6):1029-1033, 1997. 9/15/88 11/15/90 8738 (1326) Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. DR Gandara, J Crowley, RB Livingston, EA Perez, CW Taylor, G Weiss, JR Neefe, LF Hutchins, RW Roach, SM Grunberg, TJ Braun, RB Natale, SP Balcerzak. Classic Papers and Current Comments 2(1):178-184, 1997. Lung 07/01/88 06/01/90 8805 (1328) Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-smallcell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. KS Albain, VW Rusch, JJ Crowley, TW Rice, AT Turrisi III, JK Weick, VA Lonchyna, CA Presant, RJ McKenna, DR Gandara, H Fosmire, SA Taylor, KJ Stelzer, KR Beasley, RB Livingston. Classic Papers and Current Comments 2(1):145-158, 1997. Lung 7/1/88 3/15/92 8992 (1280) Induction cisplatin/vinblastine and irradiation vs irradiation Lung in unresectable squamous cell lung cancer: Failure patterns by cell type in RTOG 88-08/ECOG 4588. R Komaki, CB Scott, WT Sause, DH Johnson, SG Taylor IV, JS Lee, B Emami, RW Byhardt, WJ Curran Jr, AR Dar, JD Cox. International Journal of Radiation Oncology, Biology, Physics 30(3):537-544, 1997. 6/15/90 2/1/92 9058 (1232) A phase II trial of intravenous vinorelbine in previously Lung untreated patients with extensive small cell lung cancer, a Southwest Oncology Group study. CS Higano, JJ Crowley, RV Veith, RB Livingston. Investigational New Drugs 15:153-156, 1997. 5/15/92 6/1/95 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ 9207 (1198) Phase II trial of edatrexate plus carboplatin in metastatic Lung non-small cell lung cancer: A Southwest Oncology Group study. DR Gandara, MJ Edelman, JJ Crowley, RB Livingston. Cancer Chemotherapy and Pharmacology 41:75-78, 1997. Multiple Studies (1327) Survival determinants in extensive-stage non-small-cell lung cancer. The Southwest Oncology Group experience. KS Albain, JJ Crowley, M LeBlanc, RB Livingston. Classic Papers and Current Comments 2(1):135-144, 1997. None (1313) Summary of the proceedings of the United States - Japan Lung lung cancer clinical trials summit. RB Livingston, R Tsuchiya, M Fukushima, CA Coltman Jr. Journal of Cancer Research and Clinical Oncology 123:461-466,1997. 1/1/93 6/1/95 Lung ABSTRACTS PUBLISHED/PRESENTED 8992 (1443) Interfraction interval does not affect survival of patients with Lung non-small cell lung cancer treated with hyperfractionated radiotherapy with/without chemotherapy: A multivariate analysis of 682 RTOG patients. M Werner-Wasik, C Scott, ML Graham, C Smith, RW Byhardt, M Roach III, EJ Andras. International Journal of Radiation Oncology, Biology, Physics. 39(2)Suppl: 314(#2147), 1997. 6/15/90 2/1/92 8992 (1444) Response, toxicity, failure patterns and survival in five Lung Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy (CT) and radiation therapy (RT) for locally advanced non-small cell carcinoma of the lung (NSCLC). R Byhardt, C Scott, W Sause, B Emami, R Komaki, B Fisher, J Lee, C Lawton. International Journal of Radiation Oncology, Biology, Physics. 39:195(#120), 1997. 6/15/90 2/1/92 8992 (1445) Intensified treatment increases survival in patients with non-small cell lung cancer at what price? A quality adjusted survival analysis of Radiation Therapy Oncology Group chemoradiation studies. C Scott, B Movsa, W Sause, R. Byhardt, R Komaki, J Cox, D Johnson, C Lawton, AR Dar, T Wasserman, M Roach, JS Lee, EJ Andras. Quality of Life Research 6:718 (#345), 1997. Lung 6/15/90 2/1/92 8992 (1450) Toxicity in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy (CT) radiation therapy (RT) for locally advanced nonsmall cell carcinoma of the lung (NSCLC). R Byhardt, C Scott, W Sause, B Emami, R Komaki, B Fisher, J Lee, C Lawton. International Association of Lung Cancer 18(1):64(#244), 1997. Lung 6/15/90 2/1/92 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ 8992 (1451) Response, failure patterns and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy (CT) radiation oncology (RT) for locally advanced non-small cell carcinoma of the lung (NSCLC). R Byhardt, P Kolesar, W Sause, B Emami, R Komaki, B Fisher, J Lee, C Lawton. International Association of Lung Cancer 18(1):62 (#238), 1997. Lung 6/15/90 2/1/92 8992 (1449) Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small lung carcinoma of lung (NSCCL): Analysis of Radiation Therapy Oncology Group (RTOG) trials. JD Cox, CB Scott, B Emami, AH Russell, K Fu, M Parliament, R Komaki, L Gaspar. International Association of Lung Cancer 18:126(#491), 1997. Lung 6/15/90 2/1/92 *9019 (1240) Concurrent cisplatin/etoposide plus radiotherapy (PE+RT) Lung for pathologic stage (path TN) IIIB non-small cell lung cancer (NSCLC): a Southwest Oncology Group (SWOG) phase II study (S9019). KS Albain, JJ Crowley, AT Turrisi III, DR Gandara, WB Farrar, J Clark, KR Beasley, RB Livingston. American Society of Clinical Oncology 16:446a (#1600), 1997. 4/15/92 12/1/95 *9216 (1358) A randomized study of CODE plus thoracic irradiation Lung versus alternating CAV/EP for extensive stage small cell lung cancer (ESCLC). R Livingston, F Shepherd, K James, B Zee, A Langleben, M Kraut, J Bearden, J Goodwin, C Grafton, A Turrisi, D Walde, H Croft, J Ottaway. American Society of Clinical Oncology 16:456a (#1638), 1997. 12/15/92 4/26/96 *9307 (1275) Oral etoposide (VP) and oral cyclophosphamide (CP) for poor prognosis extensive disease (ED) small cell lung cancer (SCLC). A Southwest Oncology Group clinical and pharmacokinetic study. SM Grunberg, D Rector, K Hande, R Livingston. Lung Cancer 18(Suppl 1)(#85):24-25, 1997. 7/1/93 6/1/96 *9429 (1267) A Southwest Oncology Group (SWOG) phase II trial: Lung carboplatin and VP-16 with concurrent radiation for poor risk stage III non-small cell lung cancer. DH Lau, D Gandara, M Hazuka, J Crowley, R Livingston. American Society of Clinical Oncology 16:449a (#1612), 1997. 8/15/94 9/1/95 *Presented Lung SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1996 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED 8992 (1441) New chemotherapy/radiation therapy regiments may improve survival for patients with locally advanced unresectable non-small cell lung cancer. WJ Curren, Jr. Cope - Working with Oncology Jan/Feb:pp10-13, 1996. Lung 6/15/90 2/1/92 9127 (1023) Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma: A phase II study of the Southwest Oncology group. RA Figlin, JJ Crowley, EL Jacobs, M Muirhead, JW Goodwin, JJ Rinehart, RB Livingston. Cancer 78(5):998-1003, 1996. Lung 8/1/91 3/1/92 ABSTRACTS PUBLISHED/PRESENTED 8992 (1279) Induction cisplatin/vinblastine decreased distant metastasis Lung in unresectable squamous cell lung cancer (SCC): Failure patterns in RTOG 88-08/ECOG 4588. R Komaki, CB Scott, WT Sause, S Taylor IV, DH Johnson, R Livingston, B Emami, WJ Curran, RW Byhardt, AR Dar, AT Turrisi, JD Cox. International Journal of Radiation Oncology, Biology, Physics 36(1):206 (#96), 1996. 6/15/90 2/1/92 9207 (1147) Edatrexate and carboplatin in stage IV non-small cell lung cancer: Phase II trial of the Southwest Oncology Group (SWOG). D Gandara, M Edelman, G Smith, J Crowley, R Livingston. American Society of Clinical Oncology 15:397 (#1202), 1996. Lung 1/1/93 6/1/95 9216 (1409) Pilot study of cisplatin, doxorubicin, vincristine and etoposide (PAVE) in elderly and frail patients with small cell lung cancer (SCLC). V Westeel, N Murray, K Gelmon, M McKenzie, F Wong, J Morris, C Grafton, A Shah, V Tsang, K Goddard, K Murphy, B Sheehan, C Parsons, R Amy, R Page. Proc of the American Society of Clinical Oncology 15:377 (#1125), 1996. Lung *9308 (1163) Randomized phase III trial of cisplatin (CDDP) vs. CDDP Lung plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): Report of a Southwest Oncology Group study (SWOG-9308). AJ Wozniak, JJ Crowley, SP Balcerzak, GR Weiss, LR Laufman, LH Baker, RI Fisher, SI Bearman, SA Taylor, RB Livingston. American Society of Clinical Oncology 15:374 (#1110), 1996. 10/15/93 6/1/95 *Presented SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1995 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED 8805 (1047) Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-small cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. KS Albain, VW Rusch, JJ Crowley, TW Rice, AT Turrisi, JK Weick, VA Lonchyna, CA Presant, RJ McKenna, DR Gandara, H Fosmire, SA Taylor, KJ Stelzer, KR Beasley, RB Livingston. Journal of Clinical Oncology 13(8):1880-1892, 1995. Lung 7/1/88 3/15/92 8812 (909) Chemoradiotherapy with or without granulocytemacrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. PA Bunn, J Crowley, K Kelly, MB Hazuka, K Beasley, C Upchurch, GR Weiss, WJ Hicks, DR Gandara, S Rivkin, R Livingston. Journal of Clinical Oncology 13(7):1632-1641, 1995. Lung 5/15/89 1/1/92 8812 (1098) Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: A Southwest Oncology Group study. K Kelly, JJ Crowley, PA Bunn Jr, MB Hazuka, K Beasley, C Upchurch, GR Weiss, WJ Hicks, DR Gandara, S Rivkin, R Livingston. Journal of Clinical Oncology 13(12):2924-2930, 1995. Lung 5/15/89 1/1/92 9038 (1122) The price of success. SM Grunberg, H Burris III, R Livingston. Journal of Clincal Oncology 13:797-798, 1995. Lung 11/1/90 7/1/91 9138 (994) Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A Southwest Oncology Group study. SK Williamson, JJ Crowley, RB Livingston, TJ Panella, JW Goodwin. Investigational New Drugs 13:67-71, 1995. Lung 5/15/92 7/15/93 None (1111) An implicitly defined parametric model for censored survival data and covariates. S Piantadosi, J Crowley. Biometrics 51:249-258, 1995. Lung 2/15/93 5/1/94 ABSTRACTS PUBLISHED/PRESENTED *9229 (1077) *Presented Concurrent cisplatin (CDDP), prolonged oral etoposide (E) and vincristine (VCR) plus chest and brain irradiation (RT) induction therapy for limited-stage small cell lung carcinoma (SCLC): Preliminary report of a Southwest Oncology Group study (SWOG-9229). CR Thomas Jr, DJ Rector, KJ Stelzer, RB Livingston. ASCO 14:363 (#1111), 1995. Lung SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1994 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED 8012/8241 8367 (1076) Current management of unresectable non-small cell lung cancer. RB Livingston. Seminars in Oncology 21(5) (Suppl 10):4-13, 1994. Lung 8805 (1025) Neoadjuvant therapy: A novel and effective treatment for stage IIIb non-small cell lung cancer. VW Rusch, KS Albain, JJ Crowley, TW Rice, V Lonchyna, R McKenna Jr, K Stelzer, RB Livingston. Annals of Thoracic Surgery 58:290-295, 1994. Lung 7/1/88 3/15/92 8836 (887) Daily low-dose cisplatin plus concurrent high-dose Lung thoracic irradiation in locally advanced unresectable nonsmall-cell lung cancer: Results of a phase II Southwest Oncology Group study. MB Hazuka, JJ Crowley, PA Bunn Jr, M O'Rourke, TJ Braun, PA Bunn, RB Livingston. Journal of Clinical Oncology 12(9):1814-1820, 1994. 4/1/89 5/15/91 *None (1021) Vinorelbine (navelbine) - a new agent for the treatment of non-small cell lung cancer: A summary. CA Coltman Jr. Seminars in Oncology 21(5) (Suppl 10):1-3, 1994. Lung ABSTRACTS PUBLISHED/PRESENTED *8269 (955) Patterns of failure and second malignancies from SWOG-8269: Concurrent cisplatin (P), etoposide (E), vincristine (V), and once daily radiotherapy (RT) for the treatment of limited small-cell lung cancer (SCLC). L Janaki, D Rector, A Turrisi, J McCracken, R Livingston, S Giri, W Gordon, J Crowley. ASCO 13:331 (#1096), 1994. Lung 08/11/82 03/20/86 8269 (956) Long term follow-up (F/U) from SWOG 8269: Concurrent cisplatin (P), etoposide (E), vincristine (V) and daily thoracic radiotherapy (TRT) for the treatment of limited small-cell lung cancer (LSCLC): Patterns of failure and second tumors. A Turrisi, D Rector, LM Janaki, JD McCracken, R Livingston, SP Giri, W Gordon, J Crowley. Lung Cancer 11(Suppl 1):172 (#666), 1994. Lung 08/11/82 03/20/86 8609 (896) SWOG 8609 - A phase II trial of teniposide (VM-26) as therapy for extensive small cell lung cancer (SCLC). V Canfield, P Grozea, J Crowley, R Livingston. Lung Cancer 11(Suppl 1):102 (#389), 1994. Lung 9/15/88 11/15/90 *8805 (961) Concurrent cisplatin/etoposide (PE) + chest radiation (CRT) followed by surgery for stages 3A(N2) and 3B non-small cell lung cancer: Completed analysis of SWOG-8805. K Albain, V Rusch, J Crowley, A Turrisi, T Rice, R Livingston. ASCO 13:337 (#1120), 1994. Lung 07/01/88 03/15/92 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ *8992 (1402) RTOG 8808 ECOG 4588, Preliminary analysis of a phase III Lung trial in regionally advanced unresectable non-small cell lung cancer. W. Sause, C Scott, S Taylor, D Johnson, R Livingston, R Komaki, B Emami, W Curran, R Byhardt, R Fisher, A Turrisi. Proc of the American Society of Clinical Oncology 13:325 (#1072), 1994 8992 (1446) RTOG 8808 ECOG 4588, Preliminary analysis of a phase III Lung trial in regionally advanced Unresectable non-small cell lung cancer. W Sause, C Scott, S Taylor, D Johnson, R Livingston, R Komaki, B Emami, W Curran, R Byhardt, G Fisher, A Turrisi. Lung Cancer 11 Suppl 1:179(#695), 1994. 9038/9307 (989) Extended oral etoposide (E) and oral cyclophosphamide (C) for lung cancer. SM Grunberg, J Crowley, R Livingston. Lung Cancer 11(Suppl 1):121 (#464), 1994. Lung 9138 (1004) Phase II trial of fazarabine (FAZ) in advanced non-small cell carcinoma of the lung (NSCLC) - a clinical trial report and cost analysis: A Southwest Oncology Group study. SK Williamson, JJ Crowley, JW Goodwin, RB Livingston. ASCO 13:347 (#1160), 1994. *9252 (965) Cisplatin (P) & etoposide (E) + concurrent thoracic radiotherapy (TRT) administered once versus twice daily for limited-stage (LS) small cell lung cancer (SCLC): Preliminary results of an intergroup trial. DH Johnson, K Kim, AT Turrisi, W Sause, R Komaki, H Wagner, R Blum. ASCO 13:333 (#1105), 1994. *Presented 6/15/90 2/1/92 Lung 5/15/92 7/15/93 Lung 02/15/94 SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1993 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 8009/8215 8605 (875) Predictors of survival following relapse or progression of small cell lung cancer: Southwest Oncology Group study #8605 and an analysis of the recurrent disease data base. KS Albain, JJ Crowley, L Hutchins, D Gandara, RM O'Bryan, D Von Hoff, B Griffin, RB Livingston. Cancer 72(4):1184-1191, 1993. Lung 08/29/87 02/01/89 8385 (437) Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer: A Southwest Oncology Group study. R Chapman, J Crowley, JG Lucas, BL Hom, RB Livingston, CB Vaughn, HE Hynes. IND 11(1):91-92, 1993. Lung 02/24/84 04/26/85 8738 (795) Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: A phase III study of the Southwest Oncology Group. DR Gandara, J Crowley, RB Livingston, EA Perez, CW Taylor, G Weiss, JR Neefe, LF Hutchins, RW Roach, SM Grunberg, TJ Braun, RB Natale, SP Balcerzak. JCO 11(5):873-878, 1993. Lung 07/01/88 06/01/90 8805 (796) Surgical resection of stage IIIA and stage IIIB nonsmall cell lung cancer after concurrent induction chemoradiotherapy. VW Rusch, KS Albain, JJ Crowley, TW Rice, V Lonchyna, R McKenna, Jr, RB Livingston, BR Griffin, JR Benfield. Journal of Thoracic and Cardiovascular Surgery 105(1):97-106, 1993. Lung 07/01/88 03/15/92 8857 (798) Prolonged, alternating chemotherapy for extensive small cell lung cancer: A Southwest Oncology Group study. RB Livingston, JJ Crowley, T Thompson, SK Williamson, FJ Meyers, T O'Rourke, JR Neefe. Cancer 81(11):35093513, 1993. Lung 10/15/89 05/15/91 8915 (799) Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer: A Southwest Oncology Group study. SK Williamson, J Crowley, RB Livingston, G Weiss. IND 11:81-83, 1993. Lung 03/01/90 12/15/91 9038 (666) Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small cell lung cancer. A Southwest Oncology Group study. SM Grunberg, J Crowley, R Livingston, I Gill, SK Williamson, T O'Rourke, T Braun, ME Marshall, JK Weick, SP Balcerzak, RL Martino. JCO 11(8):1598-1601, 1993. Lung 11/01/90 07/01/91 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ None (803) Incorporation of radiotherapy fractionation in the combined-modality treatment of limited small-cell lung cancer. AT Turrisi, III. Chest 103:418S-422S, 1993. Lung ABSTRACTS PUBLISHED/PRESENTED *8812 (677) The role of alpha interferon (rINFα2a) maintenance in patients with limited stage SCLC responding to concurrent chemoradiation: A Southwest Oncology Group study. K Kelly, PA Bunn, Jr, M Hazuka, K Beasley, J Crowley, R Livingston. ASCO 12:330 (#1099), 1993. Lung 05/15/89 01/01/92 SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1992 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 8866 (544) Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung. A Southwest Oncology Group study. SK Williamson, JJ Crowley, R Livingston, A Hantel, JH Doroshow. IND 10:29-30, 1992. Lung Dev Ther 03/01/90 05/01/91 ABSTRACTS PUBLISHED/PRESENTED *8812 (839) The role of GM-CSF in limited stage SCLC: A randomized phase III study of the Southwest Oncology Group (SWOG). PA Bunn, J Crowley, M Hazuka, R Tolley, R Livingston. ASCO 11:292 (#974), 1992. Lung 05/15/89 Open *8836 (843) Concurrent daily low-dose cisplatin (LDCP) combined with chest irradiation (RT) in locally advanced non-small cell lung cancer: Preliminary results of a Southwest Oncology Group study. M Hazuka, J Crowley, P Bunn, R Livingston. ASCO 11:294 (#987), 1992. Lung 04/01/89 05/15/91 9038 (846) Treatment of stage IV non-small cell lung cancer (NSCLC) with long term administration of oral etoposide (E) and oral cyclophosphamide (C). A Southwest Oncology Group study. SM Grunberg, I Gill, JJ Crowley, R Livingston. ASCO 11:297 (#994), 1992. Lung 11/01/90 07/01/91 SOUTHWEST ONCOLOGY GROUP PUBLICATIONS 1991 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 8241 (435) A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small cell lung cancer. A Southwest Oncology Group study. JK Weick, J Crowley, RB Natale, BL Hom, S Rivkin, CA Coltman, Jr, SA Taylor, RB Livingston. JCO 9(7):1157-1162, 1991. Lung 12/23/83 11/01/84 8567 (397) Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma: A Southwest Oncology Group study. RB Vance, JJ Crowley, JS Macdonald, FR Ahmann. IND 9(1):73-75, 1991. Lung 01/03/86 08/01/87 8573 (398) Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: A Southwest Oncology Group study. GE Goodman, J Crowley, RB Livingston, SE Rivkin, K Albain, JH McCulloch. JCO 9(3):453-457, 1991. Lung 03/21/86 05/01/88 8625 (400) A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer. A Southwest Oncology Group study. CS Higano, J Crowley, RB Livingston, JW Goodwin, B Barlogie, WJ Stuckey. Cancer 67(10):2439-2442, 1991. Lung 09/01/87 01/15/88 8703 (452) Treatment of non-small cell lung cancer with vinblastine and very high dose cisplatin. A Southwest Oncology Group study. SM Grunberg, JJ Crowley, RB Livingston, FM Muggia, JS Macdonald, SK Williamson, RL Stephens. Cancer Chemotherapy and Pharmacology 28:211-213, 1991. Lung 09/01/87 06/01/89 8850 (496) Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A Southwest Oncology Group study. GK Ellis, J Crowley, RB Livingston, JW Goodwin, L Hutchins, A Allen. Cancer 67(12):2969-2973, 1991. Lung 08/15/88 06/01/90 Multiple Studies (402) Long-term survival and toxicity in small cell lung cancer: Expanded Southwest Oncology Group experience. KS Albain, JJ Crowley, RB Livingston. Chest 99:1425-1432, 1991. Lung Multiple Studies (468) Survival determinants in extensive stage non-small cell lung cancer. The Southwest Oncology Group experience. KS Albain, JJ Crowley, M LeBlanc, RB Livingston. JCO 9(9):1618-1626, 1991. Lung __________________________________________________________________________________________ PROTOCOL NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE DATE PROTOCOL ACTIVATED DATE PROTOCOL CLOSED TO PATIENT ENTRY __________________________________________________________________________________________ ABSTRACTS PUBLISHED/PRESENTED *8738 (409) Comparison of standard dose cisplatin, high dose cisplatin, and high dose cisplatin plus mitomycin in metastatic non small cell lung cancer: Preliminary results of a phase III study. DR Gandara, MT Tanaka, J Crowley, RB Livingston. ASCO 10:246 (#843), 1991. Lung 07/01/88 06/01/90 *8805 (411) Concurrent cisplatin (DDP), VP-16, and chest irradiation (RT) followed by surgery for stages IIIa and IIIb nonsmall cell lung cancer (NSCLC): A Southwest Oncology Group study. K Albain, V Rusch, J Crowley, B Griffin, K Beasley, R Livingston. ASCO 10:244 (#836), 1991. Lung 07/01/88 Open 9038 (562) Extended administration of oral etoposide and cyclophosphamide for the treatment of advanced nonsmall cell lung cancer. S Grunberg, I Gill, J Crowley, R Livingston. Sixth World Conference on Lung Cancer, 127 (#472), 1991. Lung 11/01/90 07/01/91 SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1990 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 8215 (304) Comparison of etoposide and cisplatin with bis-chloroethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group study. RM O'Bryan, JJ Crowley, PN Kim, RB Epstein, B Neilan, CA Coltman, Jr, WJ Stuckey, R Pazdur. Cancer 65(4):856-860, 1990. Lung 04/25/83 03/22/85 8232 (308) Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: A Southwest Oncology Group study. GE Goodman, J Crowley, JC Blasko, RB Livingston, TM Beck, MD Demattia, RM Bukowski. JCO 8(1):39-47, 1990. Lung 10/03/85 03/22/89 8269 (311) Concurrent chemotherapy/radiotherapy for limited smallcell lung carcinoma: A Southwest Oncology Group study. JD McCracken, LM Janaki, JJ Crowley, SA Taylor, PGS Giri, GB Weiss, W Gordon, Jr, LH Baker, A Mansouri, JP Kuebler. JCO 8(5):892-898, 1990. Lung 08/11/82 03/20/86 8490 Chemotherapy for advanced thymoma. Preliminary results of an intergroup study. PJ Loehrer, Sr, CA Perez, LM Roth, FA Greco, RB Livingston, LH Einhorn. Annals of Internal Medicine 13(7):520-524, 1990. Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: A Southwest Oncology Group pilot study. CW Taylor, J Crowley, SK Williamson, TP Miller, SA Taylor, PG Giri, RL Stephens, RB Livingston. JCO 8(11):18111817, 1990. Lung 01/19/84 03/22/85 Lung 08/29/86 08/01/87 Determinants of improved outcome in small-cell lung cancer: An analysis of the 2,580-patient Southwest Oncology Group data base. KS Albain, JJ Crowley, M LeBlanc, RB Livingston. JCO 8(9):1563-1574, 1990. Lung 08/29/86 08/01/87 8606 (340) Multiple Studies (345) ABSTRACTS PUBLISHED/PRESENTED 8606 (366) Lack of benefit for prophylactic cranial irradiation (PCI) for patients (PTS) with small cell lung cancer (SCCL) treated with an intensive, multidrug, weekly treatment program. S Williamson, C Taylor, J Crowley, S Taylor, T Miller, P Giri. ASCO 9:247 (#955), 1990. Lung *Multiple Studies (378) Does cisplatin (DDP) - based therapy improve survival in extensive non-small cell lung cancer (NSCLC)? Southwest Oncology Group studies. K Albain, J Crowley, M LeBlanc, R Livingston. ASCO 9:227 (#877), 1990. Lung SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1989 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 8460 Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer: A Southwest Oncology Group study. C Collins, CS Higano, RB Livingston, BR Griffin, MD Keppen, TP Miller. Cancer Chemo Pharm 24:128-132, 1989. Lung 11/01/84 10/01/86 09/01/87 01/15/88 ABSTRACTS PUBLISHED/PRESENTED *8625 Weekly cis-platin (CDDP) based induction for extensive non-small cell lung cancer (NSCLC) with cis-platin and VP-16 consolidation. CS Higano, J Crowley, RB Livingston. ASCO 8:227 (#882), 1989. Lung *Multiple Studies Prognostic factors in limited small cell (LSC) lung cancer reconsidered: Southwest Oncology Group (SWOG) studies. K Albain, J Crowley, R Livingston. ASCO 8:225 (#876), 1989. Lung Charles A. Coltman, Jr., M.D. 198-24-5536 SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1988 _________________________________________________________________________________________________________ PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 7828 Outcome of prophylactic and therapeutic cranial irradiation in disseminated small cell lung carcinoma: A Southwest Oncology Group study. JG Mira, TT Chen, RB Livingston, HE Wilson. Int J Rad Oncol Biol Phys 14:861-865, 1988. Lung 11/17/78 12/03/80 8068 Simultaneous chemotherapy-radiotherapy with prophylactic cranial irradiation for inoperable adeno and large cell lung carcinoma: A Southwest Oncology Group study. JG Mira, SL Taylor, RL Stephens, T Chen. Int J Rad Oncol Biol Phys 15:757-761, 1988. Lung 09/24/80 03/30/83 8384 Evaluation of fludarabine phosphate in small cell carcinoma: A Southwest Oncology Group study. JM Rainey, JB Hill, J Crowley. Invest New Drugs 6:45-46, 1988. Lung 07/20/84 03/20/86 ABSTRACTS PUBLISHED/PRESENTED *8606 Treatment of small cell lung cancer (SCCL) using an intensive, multidrug, weekly treatment program of short duration. S Williamson, C Taylor, J Crowley, S Taylor, TP Miller, P Giri. ASCO 7:195 (#751), 1988. Lung 08/29/86 08/01/87 *8606 Treatment of small cell lung cancer (SCCL) using an intensive, multidrug, weekly treatment program of short duration. S Williamson, C Taylor, J Crowley, S Taylor, TP Miller, P Giri. Proceedings of the Fifth World Conference on Lung Cancer in Interlaken, Switzerland, 6.1.25 (A106), 1988. Lung 08/29/86 08/01/87 SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1987 ________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 7924 Multimodal therapy for limited small-cell lung cancer: A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders. MS Kies, JG Mira, JJ Crowley, TT Chen, R Pazdur, PN Grozea, SE Rivkin, CA Coltman, Jr, JH Ward, RB Livingston. JCO 5(4):592600, 1987. Lung 11/02/79 10/29/82 8367 Combined treatment with chemotherapy and neutron irradiation for limited non-small cell lung cancer: A Southwest Oncology Group study. RB Livingston, BR Griffin, CS Higano, GE Laramore, SE Rivkin, RS Goldberg, SF Schulman. JCO 5(11):1716-1724, 1987. Lung 12/05/83 10/01/86 ABSTRACTS PUBLISHED/PRESENTED 8269 Concurrent chemoradiotherapy for limited small cell carcinoma of the lung (SCCL). JD McCracken, L Janaki, SA Taylor, GB Weiss, J Crowley. ASCO #C-656, 1987. Lung 08/11/82 03/20/86 8269 Concommitant chemo radiotherapy in limited small cell carcinoma of lung: Improved response and median survival. A Southwest Oncology Group study. LM Janaki, JD McCracken, SB Taylor, PGS Giri, GB Weiss, W Gordon, Jr, RB Vance, J Crowley. Presented at the 29th Annual ASTRO Meeting in Boston, October 18-23, 1987. Lung 12/01/82 03/19/86 8269 Concurrent chemoradiotherapy for limited cell carcinoma of the lung (SCCL): A Southwest Oncology Group (SWOG) study. J McCracken, L Janaki, S Taylor, G Weiss, J Crowley. Presented at the 15th International Congress of Chemotherapy in Istanbul, Turkey, July 19-24, 1987. Lung 12/01/82 03/19/86 8269 Improved response rate and medial survival with concommitant chemo radiotherapy in limited small cell carcinoma of the lung: A Southwest Oncology Group study. LM Janaki, JD McCracken, SB Taylor, PGS Giri, GB Weiss, W Gordon, Jr, RB Vance, J Crowley. Presented at the International Conference on Small Cell Lung Cancer in Ravenna, Italy, March 27-28, 1987. Lung 12/01/82 03/19/86 Charles A. Coltman, Jr., M.D. 198-24-5536 SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1986 __________________________________________________________________________________________ PROTOCOL NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE DATE PROTOCOL ACTIVATED DATE PROTOCOL CLOSED TO PATIENT ENTRY __________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 8012 Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large cell and adenocarcinoma of the lung. A Southwest Oncology study. TP Miller, TT Chen, RB Livingston, CA Coltman, RM O'Bryan, RB Vance, G Weiss, WS Fletcher, RL Stephens. JCO 4(4):502-508, 1986. Lung 08/04/80 12/22/85 8012 Large cell and adenocarcinoma of the lung: A randomized trial of chemotherapy for metastatic disease: A Southwest Oncology Group study. TP Miller, TT Chen, CA Coltman, Jr., RM O'Bryan, RB Vance, JJ Costanzi, WS Fletcher, RL Stephens, RB Livingston. JCO 11:1313-1314, 1986. Lung 08/04/80 12/22/85 8122 Combined alkylators and multiple-site irradiation for extensive small cell lung cancer: A Southwest Oncology Group study. RB Livingston, S Schulman, JG Mira, G Harker, S Vogel, CA Coltman Jr., SE Rivkin, GT Budd, SP Balcerzak. Cancer Treat Rep 70(12):1395-1401, 1986. Lung 03/30/82 03/22/85 8261 Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): A Southwest Oncology Group study. TP Miller, RB Vance, FR Ahman, SR Rodney. Cancer Treat Rep 70(9):1101-1104, 1986. Lung 02/22/82 01/31/83 8464 A phase-II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung - A Southwest Oncology Group study. GR Weiss, JJ Crowley, DD Von Hoff, SA Taylor, RJ Belt, CA Coltman Jr., HE Hynes, JJ Costanzi. Cancer Treat Rep 70(9):1123-1124, 1986. Lung 10/03/84 01/11/85 Charles A. Coltman, Jr., M.D. 198-24-5536 __________________________________________________________________________________________ PROTOCOL NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE DATE PROTOCOL ACTIVATED DATE PROTOCOL CLOSED TO PATIENT ENTRY __________________________________________________________________________________________ ABSTRACTS PUBLISHED/PRESENTED 7924 Age and patient outcome in limited small cell lung cancer. The Southwest Oncology Group (SWOG) experience. BA Neilan, R Paloyan, J Crowley, JG Mira, MS Kies. ASCO 5: 182 (#713), 1986. Lung 11/02/79 10/29/82 8232 Concurrent chemotherapy with VP-16/vincristine/ adriamycin/cyclophosphamide (EVAC) versus alternating chemotherapy with VP-16/cis-platinum and vincristine/adriamycin/cyclophosphamide (VPP/VAC) in limited small cell lung cancer (SCLC): A Southwest Oncology Group study (SWOG). GE Goodman, J Basko. ASCO 5:169 (#663), 1986. Lung 12/01/82 10/03/84 8241 Treatment for advanced non-small cell lung cancer (NSCLC): platinum and VP-16 (PVp) + MGBG (PVpM) vs. platinum and vinblastine (PVe) + mitomycin-C (PVeMI) vs. 5-FU + vincristine + mitomycin-C/cyclophosphamide + doxorubicin + platinum (FOMi/CAP). J Weick, R Natale, J Crowley, B Hom, R Livingston. ASCO 5:177 (#692), 1986. Lung 12/23/82 11/01/84 *8269 Concurrent chemoradiotherapy for limited small cell carcinoma of the lung. A Southwest Oncology Group study. JD McCracken, LM Janaki, SA Taylor, PGS Giri, GB Weiss, W Gordon Jr. Recent Advances in Chemotherapy, Anticancer Section, Proc. of 14th Int. Congress of Chemotherapy, Kyoto, 1985 1986: 1138-1139. Lung 08/11/82 03/20/86 8367 Sequential chemotherapy and neutron irradiation (XRT) for limited non small cell lung cancer (NSCLC): A Southwest Oncology Group study. R Livingston, B Griffin, S Schulman. ASCO 5:169 (#661), 1986. Lung 12/01/83 10/01/86 8460 Cyclophosphamide, vincristine, platinum and etoposide (COPE) and radiation therapy for extensive small cell lung cancer (SCLC). A Southwest Oncology Group study. C Collins, T Higano, T Miller, R Livingston. ASCO 5: 181 (#711), 1986. Lung 11/01/84 10/01/86 SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1985 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 7628 Effect of initial resection in small cell carcinoma of the lung: A review of Southwest Oncology Group study 7628. GG Freiss, JC McCracken, ML Troxell, R Pazdur, CA Coltman Jr., HJ Eyre. JCO 3(7): 964-968, 1985. Lung 10/28/76 03/14/79 8012 Phase II trial of 5-fluorouracil, vincristine, and mitomycinC (FOMi) in metastatic bronchioalveolar cell lung cancer. A Southwest Oncology Group study. TP Miller, RB Livingston. Cancer Treat Rep 69(11):1313-1314, 1985. Lung 08/04/80 12/23/82 8012 Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large cell and adenocarcinoma of the lung. A Southwest Oncology Group study. TP Miller, TT Chen, RB Livingston, CA Coltman, RM O'Bryan, RB Vance, G Weiss, WS Fletcher, RL Stephens. J Clin Onc 4(4):502-508, 1985. Lung 08/04/80 12/23/82 8260 Treatment of non-small cell bronchogenic carcinoma with vinblastine and mitomycin: A Southwest Oncology Group study. JK Weick, JM Rainey, RB Livingston, LH Baker, RM O'Bryan, TT Chen. Cancer Treat Rep 69:583-585, 1985. Lung 05/26/82 12/23/82 ABSTRACTS PUBLISHED/PRESENTED 8112 Combination chemotherapy of unfavorable histology non-Hodgkin's lymphomas with CHOP-PVB: A Southwest Oncology Group study. L Dabich, P Grozea, R Pugh, R Bukowski, J Bonnet, S Balcerzak, E Van Slyck, M Leipman, A Lobuglio, S Jones. ASCO, #C-498, 1985. Lung 01/05/82 12/23/82 8122 Radiation therapy (XRT) to multiple sites as consolidation for extensive small cell lung cancer: Southwest Oncology Group study. R Livingston, S Schulman. ASCO, #C-698, 1985. Lung 03/30/82 03/22/85 8232 Concurrent chemotherapy with VP-16/vincristine/ adriamycin/cyclophosphamide (EVAC) versus alternating chemotherapy with VP-16/cis-platinum and vincristine/adriamycin/cyclophosphamide (VPP/VAC) in limited small cell lung cancer (SCLC): A Southwest Oncology Group (SWOG) study. GE Goodman, J Basko. Proc ASCO 5:169(#663), 1985. Lung 12/01/82 10/03/84 8269 Concurrent chemoradiotherapy for limited small cell carcinoma of the lung (SCCL). JD McCracken, L Janaki, SA Taylor, GB Weiss. A Southwest Oncology Group limited institutional pilot study. ASCO, #C-683, 1985. Lung 08/11/82 03/20/86 *8367 Sequential chemotherapy and neutron irradiation (XRT) for limited non small cell lung cancer (NSCLC): A Southwest Oncology Group study. R Livingston, B Griffin, S Schulman. ASCO, #C-504, 1985. Lung 12/05/83 10/01/86 SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1984 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 7415 Long-term survival and toxicity in small cell lung cancer. Southwest Oncology Group study. RB Livingston, RL Stephens, JD Bonnet, PN Grozea, DE Lehane. Am J Med 77:415-417, 1984. Lung 7828 Combined modality treatment of extensive small cell lung cancer. A Southwest Oncology Group study. RB Livingston, JG Mira, TT Chen, M McGavran, JJ Costanzi, M Samson. J Clin Oncol 2:585-590, 1984. Lung *7828 Relation of relapsing sites after chemotherapy to initial sites Lung of involvement in disseminated small cell lung carcinoma: Possible role of consolidation radiotherapy. A Southwest Oncology Group study. JG Mira, RB Livingston, TT Chen, TN Moore, SP Balcerzak. In: IASLC Workshop on Radiotherapy for Lung Cancer (Cambridge, England, July 1984). Multiple Studies Adenocarcinoma of the lung in patients younger than 35 years. BL Hom. JAMA 252 (15):2007, 1984. Lung ABSTRACTS PUBLISHED/PRESENTED 7628 Improved long term survival associated with surgery in limited small cell cancer of the lung (SCCL). A Southwest Oncology Group (SWOG) study. G Friess, J McCracken, G Clark, M Troxell. ASCO, #C-857, 1984. Lung *7924 Chest relapses outside radiotherapy field and possible improvement of routine use of chest-computerized tomography during treatment planning of lung cancer. JG Mira, MS Kies, TT Chen, JL Potter, PN Grozea, LH Baker, RB Livingston. IASLC Workshop on Radiotherapy for Lung Cancer (Cambridge, England, July 1984). Lung *7924 Influence of chest radiotherapy (RT) in response, remission duration, and survival in chemotherapy (CT) responders in localized small cell lung carcinoma (SCLC): A Southwest Oncology Group (SWOG) study. JG Mira, MS Kies, T Chen. ASCO, #C-827, 1984. Lung 8068 Simultaneous chemotherapy/radiotherapy with prophylactic cranial irradiation for inoperable adeno and large cell lung carcinoma. A Southwest Oncology Group pilot study. JG Mira, TT Chen, CK Osborne, SA Taylor. American Society of Therapeutic Radiologists , 1984. Lung *8122 Extensive small cell lung cancer: Combined alkylators for induction with Cisplatin + VP-16 consolidation. A Southwest Oncology Group study. R Livingston, J Mira. ASCO, #C-821, 1984. Lung 8261 Treatment of advanced non-small cell lung cancer (NSCLC) with Mitomycin C + Cis-Platinum + Vindesine (MiPE): Comparisons to other Mitomycin C + VINCA-containing combinations (for the Southwest Oncology Group). TP Miller, RB Vance, TC Tong. ASCO, #C-898, 1984. Lung Multiple Studies Resectability of small cell lung cancer (SCLC), timing, and incidence in a community setting. B Marchello, N Hammond, P Teel, J Hanson, G Glenn, F Deigert. ASCO, #C-911, 1984. Lung SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1983 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 7807 Evaluation of single-agent Cisplatin in the management of non-small cell carcinoma of the lung. A Southwest Oncology Group study. FJ Panettiere, RB Vance, WJ Stuckey, CA Coltman Jr, JJ Costanzi, TT Chen. Cancer Treat Rep 67:399-400, 1983. Lung 7832 High-dose chlorozotocin in lung cancer. A Southwest Oncology Group Phase II study. CD Haas, RL Stephens, RM Bukowski, WJ Stuckey, JD McCracken, RG Gagliano, DE Lehane, RP Pugh. Cancer Treat Rep 67:705-707, 1983. Lung 7963 Phase II evaluation of Amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: A University of Arizona and Southwest Oncology Group study. FR Ahmann, F Meyskens Jr, SE Jones, RM Bukowski, JH Saiers, DH Ryan, J Costanzi, CB Vaughn, CA Coltman Jr. Cancer Treat Rep 67:697-700, 1983. Melanoma, Myeloma, Lymphoma, Lung, Breast 8003 Phase II evaluation of MGBG in non-small cell carcinoma of the lung. A Southwest Oncology Group study. RB Vance, WA Knight III, TT Chen, JJ Costanzi, AF LoBuglio. Investigational New Drugs 1:089-093, 1983. Lung 8009 Mitoxantrone for treatment of patients with refractory small cell carcinoma of the lung: A Southwest Oncology Group study. DD Von Hoff, T Chen, GM Clark, SK Callahan, R Livingston and the Southwest Oncology Group. Cancer Treat Rep 67:403-404, 1983. Lung 8015 Evaluation of two combination chemotherapy programs: Adriamycin and Cis-Platinum (AP) versus Adriamycin, Cis-Platinum plus VP16-213 (VAP) in the treatment of extensive squamous cell carcinoma of the lung. A Southwest Oncology Group study. Phase III (preliminary data). PN Grozea, B Hom, TT Chen, JJ Costanzi, SP Balcerzak, RM O'Bryan, M Lane, RL Stephens, SC Dodd-Taylor, RB Livingston. In: 13th International Congress of Chemotherapy (Vienna, August 28-September 2, 1983). Lung ABSTRACTS PUBLISHED/PRESENTED *7415 Long-term survivors with small-cell lung cancer (SCLC): A Southwest Oncology Group (SWOG) study. RB Livingston. ASCO, #C-730, 1983. Lung *7828 Outcome of prophylactic and therapeutic cranial irradiation in disseminated small lung carcinoma. A Southwest Oncology Group study. JG Mira, TT Chen, RB Livingston, SP Balcerzak. IASLC Workshop on Radiotherapy for Lung Cancer (Cambridge, England, July 1984). Lung *8012 Alternating combination chemotherapy prolongs survival for metastatic non-small cell lung cancer (NSCLC) (for the Southwest Oncology Group). TP Miller, TT Chen. ASCO, #C-733, 1983. Lung SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1982 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 7415/7628/ 7828 Isolated pleural effusion in small cell lung carcinoma: Favorable prognosis. A review of the Southwest Oncology Group experience. RB Livingston, JD McCracken, CJ Trauth, TT Chen. Chest 81:208-211, 1982. Lung 7415/7828 Influence of chest radiotherapy in frequency and patterns of chest relapse in disseminated small cell lung carcinoma: A Southwest Oncology Group study. JG Mira, RB Livingston, TN Moore, TT Chen, F Batley, CR Bogardus, B Considine, CM Mansfield, J Schlosser, HG Seydel. Cancer 50: 1266-1272, 1982. Lung 7628 Combination chemotherapy, radiotherapy and BCG immunotherapy in limited small-cell carcinoma of the lung. JD McCracken, T Chen, J White, VK Vaitkevicius, R Stephens, CA Coltman Jr, J Saiki, M Lane, J Bonnet, M McGavran. Cancer 49:2252-2258, 1982. Lung 7628 The influence of radiation therapy quality control on survival, Lung response and sites of relapse in oat cell carcinoma of the lung preliminary report of a Southwest Oncology Group study. JE White, TT Chen, JD McCracken, P Kennedy, HG Seydel, G Hartman, J Mira, M Khan, FY Durrance, O Skinner. Cancer 50:1084-1090, 1982. 7635 Limited squamous cell carcinoma of the lung: A Southwest Oncology Group randomized study of radiation with or without Doxorubicin chemotherapy and with or without Levamisole immunotherapy. JE White, T Chen, R Reed, J Mira, WJ Stuckey, T Weatherall, R O'Bryan, MK Samson, HG Seydel. Cancer Treat Rep 66:1113-1120, 1982. Lung 7769 Influence of chest radiotherapy in frequency and patterns of chest relapse in disseminated small cell lung carcinoma. A Southwest Oncology Group study. JG Mira, RB Livingston, TN Moore, TT Chen, F Batley, CR Bogardus, B Considine, CM Mansfield, J Schlosser, HG Seydel. Cancer 50(7): 1266-1272, 1982. Lung 7971 Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, Vindesine, and Mitomycin-C (FEMi): A Southwest Oncology Group study. TP Miller, JK Weick, PN Grozea, DA Carlin. Cancer Treat Rep 66:553-556, 1982. Lung ABSTRACTS PUBLISHED/PRESENTED ? Response to vindesine or vincristine in inoperable non-small Lung cell carcinoma of the bronchus. SG Spiro, RL Souhami, JS Tobias, J Jewkes, PG Harper, DM Geddes. Eur J Respir Dis 63(Suppl 25):56, 1982. ? A clinicopathologic study of small cell onaplastic carcinoma. ME Hammond, WT Sause, RL Flinner, RB Livingston. 24th Annual Meeting of the American Society of Therapeutic Radiologists (Orlando, October 25-29, 1982). Lung *7828 Reinduction prolongs survival in complete responders (CR) with small cell lung cancer. RB Livingston, RL Greenstreet. ASCO, #C-589, 1982. Lung 7828 Evaluation of two different techniques for prophylactic cranial irradiation of small cell lung carcinoma. JG Mira. ASTR Poster Abstracts, p. 26, #C14, October 1982. Lung *7924 Value of chest radiation (RT) in limited small cell lung cancer after chemotherapy (CT)-induced complete disease remission (for the Southwest Oncology Group). MS Kies, J Mira, T Chen, RB Livingston. ASCO, #C-546, 1982. Lung 8009 Mitoxantrone for oat cell carcinoma of the lung: In vivo and in vitro results. SK Callahan, DD Von Hoff, GM Clark, T Chen, J Mira, R Livingston and the Southwest Oncology Group. ASCO, #C-594, 1982. Lung SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1981 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 7520 Phase II evaluation of Dianhydrogalactitol in lung cancer: A Southwest Oncology Group study. CD Haas, LH Baker, T Thigpen. Cancer Treat Rep 65:115-117, 1981. Lung 7867 Four-drug combination chemotherapy in extensive non-small cell lung cancer: A Southwest Oncology Group pilot study. RB Livingston, JG Mira, RM O'Bryan. Cancer Treat Rep 65:143-144, 1981. Lung 7971 Treatment of advanced adenocarcinoma and large cell undifferentiated carcinoma of the lung with 5-Fluorouracil, vincristine (FOMi) or vindesine (FEMi), and Mitomycin C: A preliminary analysis. TP Miller. In: Proceedings of the International Vinca Alkaloid Symposium - Vindesine . S. Karger, 1981. Lung ABSTRACTS PUBLISHED/PRESENTED 7415/7628/ 7828 Isolated pleural effusion in small cell lung carcinoma: a favorable prognostic group. RB Livingston, JD McCracken, TT Chen. AACR, #793, 1981. Lung 7628 Combination chemotherapy, radiotherapy and BCG immunotherapy in ?. JD McCracken, T Chen, J White. 12th International Congress of Chemotherapy (International Society of Chemotherapy, Florence, July 19-24, 1981), 301, 1981. Lung 7629/7806/ 7807 Cis-platinum (CACP) toxicity. An analysis based on 3 Southwest Oncology Group studies. FJ Panettiere. AACR, #623, 1981. Head & Neck, GI, Lung 7828 The value of reinduction chemotherapy in extensive small cell lung cancer. RB Livingston, RL Greenstreet. ASCO, #C-666, 1981. Lung SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1980 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 7628 Combination chemotherapy, radiotherapy and BCG immunotherapy in extensive (metastatic) small cell carcinoma of the lung: A Southwest Oncology Group study. JD McCracken, L Heilbrun, J White, R Reed, M Samson, JH Saiers, R Stephens, WJ Stuckey, J Bickers, R Livingston. Cancer 46: 2335-2340, 1980. Lung ABSTRACTS PUBLISHED/PRESENTED 7628 Radiation therapy in limited oat cell carcinoma of the lung. JE White, JD McCracken, TT Chen. ASCO, #C-80, 1980. Lung 7628 Adverse effect of BCG immunotherapy combined with chemotherapy/radiotherapy in metastatic small cell carcinoma of the lung. JD McCracken, JE White, MK Samson, JH Saiers, RB Livingston. ASCO, #C-502, 1980. Lung 7628 The influence of radiation therapy quality control on survival in oat cell carcinoma of the lung. JE White, JD McCracken, TT Chen. Abstracts: II World Conference on Lung Cancer, #174, 1980. Lung 7628 The influence of radiation therapy on response, survival and patterns of relapse in limited oat cell carcinoma of the lung. JE White, JD McCracken, TT Chen. Proceedings of American Society of Therapeutic Radiologists , #4, 1980. Lung 7807 Effects of the two-dose Southwest Oncology Group Cis-platinum (CACP) program in non-oat cell lung cancer. FJ Panettiere. ASCO, #C-517, 1980. Lung 7828 Non-cross-resistant combinations in patients (PTS) with extensive small cell lung cancer. R Livingston, J Mira. ASCO, #C-512, 1980. Lung 7963 A broad Phase II trial of AMSA with in vitro stem cell culture drug sensitivity correlation. F Ahmann, F Meyskens, S Jones, B Durie, D Alberts, S Salmon. ASCO, #C-199, 1980. Breast, Lung, Lymphoma, Melanoma, Myeloma SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1979 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 7769 Unexpected toxicity of combined modality therapy for small cell carcinoma of the lung. A Southwest Oncology Group study. RB Livingston, J Mira, C Haas, L Heilbrun. Int J Rad Onc Bio Phys 5: 1637-1641, 1979. 1 Lung SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1978 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED ?7415 Combined modality treatment of small cell carcinoma of the lung. RB Livingston, TE Moore. Advances in Cancer Chemotherapy, Proceedings of the 8th International Symposium of the Princess Tokamatso Cancer Research Fdn., Tokyo, Japan, 1977. Carter SDK, Goldin A, Kuretani K, Mathe G, Sakurai Y, Tsukagash S, Umezawa H, eds. Baltimore, University Park Press:506, 1978. Lung 7415 An acceptable rate of complications in combined doxorubicin-irradiation for small cell carcinoma of the lung. A Southwest Oncology Group study. TN Moore, R Livingston, L Heilburn, FY Durrance, D Test, B Hickman, C Bogardus. Int J Radiat Oncol Biol Phys 4(7-8):675-680, 1978. Lung 7415 The effectiveness of prophylactic brain irradiation in small cell carcinoma of the lung: A Southwest Oncology Group study. TN Moore, RB Livingston, L Heilbrun, J Eltringham, O Skinner, J White, D Tesh. Cancer 41(6):2149-2153, 1978. Lung 7415 Small-cell carcinoma of the lung: Combined chemocancer and radiation. RB Livingston, T Moore, L Heilbrun, R Bottomley, D Lehane, SE Rivkin, T Thigpen. Ann Intern Med 88(2):194-199, 1978. Lung 7439 Patterns of response and relapse in chemotherapy of extensive squamous carcinoma of the lung. RB Livingston, LH Heilbrun. Cancer Chemo & Pharmacol 1:225-227, 1978. Lung 7766 Adriamycin and chlorambucil versus adria and thiabendzole in the treatment of extensive non-small cell carcinoma of the lung. A Southwest Oncology Group study. RB Livingston, LH Heilbrun, T Thigpen, CA Coltman, Jr, C Haas. Cancer Treat Rep 62(8):1215-1217, 1978. Lung 1 ABSTRACTS PUBLISHED/PRESENTED ? Postoperative radiation therapy in carcinoma of the lung. JE White, M Boles. Int J Rad Oncol Biol Phys 4(Suppl. 2):104, 1978. Lung 7415 Response and survival update in combined modality treatment of small cell carcinoma of the lung. CJ Trauth, RB Livingston, TN Moore. ASCO 19:406 (#C-398), 1978. Lung 7628 Combination chemotherapy, radiotherapy and immunotherapy for oat cell carcinoma of the lung. JD McCracken, J White, R Reed, R Livingston, B Hoogstraten. ASCO 19:395 (#C-354), 1978. Lung 2 SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1977 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED 7439 Comparative trial of combination chemotherapy in extensive squamous carcinoma of the lung: a Southwest Oncology Group study. RB Livingston, L Heilbrun, D Lehane, JJ Costanzi, R Bottomley, RL Palmer, WJ Stuckey and B Hoogstraten. Cancer Treat Rep 61:1623-1629, 1977. Lung ABSTRACTS PUBLISHED/PRESENTED 7415 Prognostic significance of pretreatment variables in small cell carcinoma of the lung. RC Reed and RB Livingston. ASCO, #C-162, 1977. Lung 7415 Responses in oat cell carcinoma: survival and recurrence patterns. RB Livingston, TN Moore, L Heilbrun. Proc AACR 18:142 (#568), 1977. Lung 1 SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1976 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ ABSTRACTS PUBLISHED/PRESENTED *7376 The natural history of lung involvement in histiocytosis X. D Komp, V Land, C Perez, K Starling and M Haynes. ASCO, #C-65, 1976. Lung *7415 Combined modality treatment of oat cell carcinoma of the lung. RB Livingston and TN Moore. AACR, #606, 1976. Lung *7439 Comparison of 3-drug and 5-drug combination chemotherapy in extensive squamous lung cancer. R Livingston, T Thigpen and J Hart. ASCO, #C-148, 1976. Lung 1 SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1975 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ ABSTRACTS PUBLISHED/PRESENTED *972 Combination chemotherapy in disseminated lung cancer. JD Bearden III and CA Coltman, Jr. ASCO, #1118, 1975. 1 Lung SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1969 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED ? Procarbazine (NSC-77213) in the treatment of advanced brochogenic carcinoma. ML Samuels, WV Leary, CD Howe. Cancer Chemotherapy Reports 53(2):135-145, 1969. 1 Lung SOUTHWEST ONCOLOGY GROUP PUBLICATIONS LIST 1964 _________________________________________________________________________________________________________ DATE PROTOCOL DATE CLOSED TO PROTOCOL PROTOCOL PATIENT NUMBER PUBLICATIONS (TITLE & CITATION) DISEASE ACTIVATED ENTRY _________________________________________________________________________________________________________ MANUSCRIPTS PUBLISHED/PRESENTED ? Phase II studies of hydroxyurea (NSC-32065) in adults: Carcinoma of the lung. JN Bickers. Cancer Chemotherapy Reports 40:45-46, 1964. 1 Lung
Related documents